Anti-LRRC15 antibody and use thereof

By developing antibodies or antigen-binding fragments that specifically bind to LRRC15, the problem of insufficient LRRC15-targeting drugs in existing technologies has been solved, achieving effective treatment for a variety of tumors.

WO2026238077A1PCT designated stage Publication Date: 2026-11-19JIANGSU SIMCERE ZAIMING PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/097079
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-04-27
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a lack of effective drugs targeting LRRC15 in the current technology, which cannot effectively inhibit its high expression in tumors, resulting in insufficient anti-tumor activity.

Method used

Develop antibodies or antigen-binding fragments that specifically bind to LRRC15, containing specific HCDR and LCDR amino acid sequences, to bind with high affinity to LRRC15 and inhibit tumor cells through effector functions such as ADCC and CDC.

Benefits of technology

It achieves highly efficient and specific binding to LRRC15, significantly inhibits the proliferation and migration of tumor cells, and has potential anti-tumor activity, making it suitable for the treatment of various tumor types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026097079-FTAPPB-I100001
    Figure PCTCN2026097079-FTAPPB-I100001
  • Figure PCTCN2026097079-FTAPPB-I100002
    Figure PCTCN2026097079-FTAPPB-I100002
  • Figure PCTCN2026097079-FTAPPB-I100003
    Figure PCTCN2026097079-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are an LRRC15 antibody and use thereof, and specifically, provided are an antibody or an antigen-binding fragment that specifically binds to human LRRC15, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid molecule, a vector, a cell, a preparation method, a pharmaceutical composition, pharmaceutical use, and a method for treating a disease, which are of great significance for developing drugs for treating LRRC15-expressing tumors or cancers.
Need to check novelty before this filing date? Find Prior Art

Description

An anti-LRRC15 antibody and its application

[0001] Cross-reference to related applications

[0002] This application claims priority and benefit to Chinese patent application No. 202510630540.6 filed on May 16, 2025, and Chinese patent application No. 202610568808.2 filed on April 27, 2026, both of which are incorporated herein by reference in their entirety for all purposes. Technical Field

[0003] This disclosure relates to the pharmaceutical field, and more specifically to antibodies that specifically bind to LRRC15, and their use in the treatment of tumors. Background Technology

[0004] LRRC15 (Leucine Rich Repeat Containing 15), also known as HLib and LIB, is a type I transmembrane protein rich in 15 leucine repeat sequences and a member of the LRRC superfamily. Structurally, LRRC15 consists of 581 amino acids, mainly including an N-terminal transmembrane domain, 15 leucine-rich repeat sequences (LRRs), and a short C-terminal cytoplasmic tail. Studies have shown that LRRC15 can participate in protein-protein and protein-matrix interactions, thereby affecting cell-matrix adhesion and cell migration.

[0005] LRRC15 expression has been shown to be induced by TGF-β signaling, primarily expressed on epithelial-derived cells such as fibroblasts and mesenchymal cells, and also in normal tissues such as hair follicles, tonsils, and wound healing sites. In tumors, multiple studies have shown that LRRC15 is not only highly expressed in mesenchymal-derived tumor cells (such as sarcoma, glioblastoma, and melanoma), but also overexpressed in stromal fibroblasts within the tumor microenvironment of breast cancer, head and neck tumors, lung tumors, and pancreatic tumors. Summary of the Invention

[0006] Given that drugs that inhibit LRRC15 expression have potential anti-tumor activity, there is a high clinical demand and great application potential for developing drugs that target LRRC15.

[0007] This disclosure provides antibodies or antigen-binding fragments that specifically bind to LRRC15, corresponding multispecific antigen-binding molecules, chimeric antigen receptors, immune effector cells, nucleic acid fragments, vectors, host cells, pharmaceutical compositions, methods of preparation thereof, pharmaceutical uses, and applications in the treatment of tumors.

[0008] In a first aspect, this disclosure provides an antibody or antigen-binding fragment that specifically binds to LRRC15, said antibody or antigen-binding fragment comprising:

[0009] (a) a heavy chain variable region VH, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3; and / or,

[0010] (b) Light chain variable region VL, which includes LCDR1, LCDR2 and LCDR3.

[0011] In some embodiments, the HCDR1, HCDR2, and HCDR3 have amino acid sequences of HCDR1, HCDR2, and HCDR3 with VH as shown in any one of SEQ ID NO: 13-14, 53-55, 62-64, and 80, or have at least 70% identity or at most 3 mutated amino acid sequences compared to the amino acid sequences of the HCDR1, HCDR2, and HCDR3.

[0012] In some embodiments, LCDR1, LCDR2, and LCDR3 have the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL as shown in any one of SEQ ID NO:15-16, 52, 61, and 77, or have at least 70% identity or at most 3 mutated amino acid sequences compared to the amino acid sequences of LCDR1, LCDR2, and LCDR3.

[0013] Preferably, the HCDR1-3 and / or the LCDR1-3 are selected from Table 4, Table 15, Table 20 or Table 30.

[0014] In some embodiments, the antibody or antigen-binding fragment comprises:

[0015] (1) The amino acid sequence of HCDR1-3 of VH shown in any one of SEQ ID NO:13 and 53-55, and the amino acid sequence of LCDR1-3 of VL shown in SEQ ID NO:15 or 52, or an amino acid sequence having at least 70% identity or at most 3 mutations compared to the above amino acid sequences; or,

[0016] (2) The amino acid sequences of HCDR1-3 of VH shown in any one of SEQ ID NO:14 and 62-64, and the amino acid sequences of LCDR1-3 of VL shown in SEQ ID NO:16 or 61; or amino acid sequences having at least 70% identity or at most 3 mutations compared to the above amino acid sequences; or,

[0017] (3) The amino acid sequences of HCDR1-3 of VH shown in any one of SEQ ID NO:78-80, and the amino acid sequences of LCDR1-3 of VL shown in SEQ ID NO:77; or an amino acid sequence having at least 70% identity or at most 3 mutations compared with the above amino acid sequences.

[0018] In some specific embodiments, the antibody or antigen-binding fragment comprises:

[0019] (1) The amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:13, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:15.

[0020] (2) The amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:14, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:16.

[0021] (3) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH as shown in any one of SEQ ID NO:53-55, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO:52; or

[0022] (4) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH as shown in any one of SEQ ID NO:62-64, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO:61. In some specific embodiments, the HCDR1-3 have amino acid sequences selected from the group consisting of:

[0023] Amino acid sequences such as those shown in SEQ ID NO:17-19; SEQ ID NO:29-31; SEQ ID NO:39-40 and 19; or SEQ ID NO:17-18 and 60, or amino acid sequences having at least 70% identity or at most 3 mutations compared to the above amino acid sequences; or,

[0024] The HCDR1-3 has an amino acid sequence selected from the following group:

[0025] Amino acid sequences such as those shown in SEQ ID NO:23-25; SEQ ID NO:34-36; or SEQ ID NO:41-42 and 25, or amino acid sequences having at least 70% identity or at most 3 mutations compared to the above amino acid sequences; or,

[0026] The HCDR1-3 has an amino acid sequence as shown in SEQ ID NO:87 and 85-86, or an amino acid sequence with at least 70% identity or up to 3 mutations compared to the above amino acid sequences.

[0027] In some specific embodiments, the LCDR1-3 has an amino acid sequence selected from the group consisting of:

[0028] Such as the amino acid sequences shown in SEQ ID NO:20-22; or SEQ ID NO:32-33 and 22, or amino acid sequences having at least 70% identity or at most 3 mutations compared to the above amino acid sequences; or,

[0029] The LCDR1-3 has an amino acid sequence selected from the group consisting of:

[0030] Such as the amino acid sequences shown in SEQ ID NO:26-28; or SEQ ID NO:37-38 and 28, or amino acid sequences having at least 70% identity or at most 3 mutations compared to the above amino acid sequences; or,

[0031] The LCDR1-3 has an amino acid sequence as shown in SEQ ID NO:88-90, or an amino acid sequence with at least 70% identity or up to 3 mutations compared to the above amino acid sequence.

[0032] Preferably, the HCDR1-3 and / or the LCDR1-3 are determined according to the Kabat, Chothia or IMGT method.

[0033] In some specific embodiments, the HCDR1-3 and the LCDR1-3 each have a sequence selected from the group consisting of:

[0034] (1) The HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:17-19, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:20-22; or

[0035] The HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:29-31, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:32-33 and SEQ ID NO:22; or

[0036] The HCDR1-HCDR3 have the amino acid sequences shown in SEQ ID NO:39-40 and 19, respectively, and the LCDR1-LCDR3 have the amino acid sequences shown in SEQ ID NO:20-22, respectively; or

[0037] The HCDR1-HCDR3 have the amino acid sequences shown in SEQ ID NO: 17-18 and 60, respectively, and the LCDR1-LCDR3 have the amino acid sequences shown in SEQ ID NO: 20-22, respectively; or

[0038] (2) The HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:23-25, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:26-28; or

[0039] The HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:34-36, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:37-38 and 28; or

[0040] The HCDR1-HCDR3 have the amino acid sequences shown in SEQ ID NO:41-42 and 25, respectively, and the LCDR1-LCDR3 have the amino acid sequences shown in SEQ ID NO:26-28, respectively; or

[0041] (3) The HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:87 and 85-86, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:88-90; or

[0042] (4) An amino acid sequence that has at least 70% identity or at most 3 mutations compared to the amino acid sequences in groups (1)-(3) above.

[0043] In some specific embodiments, the heavy chain variable region VH comprises an amino acid sequence as shown in any one of SEQ ID NO: 13-14, 53-55, 62-64, and 78-80, or an amino acid sequence having at least 70% identity or up to 15 mutations compared to it; and / or,

[0044] The light chain variable region VL contains an amino acid sequence as shown in any one of SEQ ID NO:15-16, 52, 61 and 77, or an amino acid sequence having at least 70% identity or up to 15 mutations compared to it.

[0045] In some specific embodiments, the antibody or antigen-binding fragment comprises:

[0046] (1) VH as shown in SEQ ID NO:13, and VL as shown in SEQ ID NO:15;

[0047] (2) VH as shown in SEQ ID NO:14, and VL as shown in SEQ ID NO:16;

[0048] (3) VH as shown in any one of SEQ ID NO:53-55, and VL as shown in SEQ ID NO:52;

[0049] (4) VH as shown in any one of SEQ ID NO:62-64, and VL as shown in SEQ ID NO:61; or

[0050] (5) VH as shown in any one of SEQ ID NO:78-80 and VL as shown in SEQ ID NO:77.

[0051] In some specific embodiments, the antibody or antigen-binding fragment further comprises a heavy chain constant region CH and / or a light chain constant region CL; optionally, the heavy chain constant region and / or light chain constant region are selected from a complete constant region sequence or a fragment thereof, the constant region fragment including CH1, a hinge region, CH2, CH3, CL or Fc region; optionally, the heavy chain constant region is selected from human or mouse IgG1, IgG2, IgG3 or IgG4 constant regions, and the light chain constant region is selected from human or mouse kappa constant regions or lambda constant regions.

[0052] In some specific embodiments, the heavy chain constant region of the antibody or antigen-binding fragment has the amino acid sequence shown in SEQ ID NO:5.

[0053] In some specific embodiments, the light chain constant region of the antibody or antigen-binding fragment has the amino acid sequence shown in SEQ ID NO:7.

[0054] In some embodiments, the antibody or antigen-binding fragment includes a heavy chain variable region VH, which includes HCDR1, HCDR2, and HCDR3.

[0055] In some embodiments, the HCDR1, HCDR2, and HCDR3 have the amino acid sequences of HCDR1, HCDR2, and HCDR3 as shown in any one of SEQ ID NO:43 and 69-71, or have at least 70% identity or at most 3 mutated amino acid sequences compared to the above amino acid sequences.

[0056] Preferably, the HCDR1-3 and / or the LCDR1-3 are selected from Table 8 or Table 24.

[0057] In some specific embodiments, the HCDR1-3 has an amino acid sequence selected from the group consisting of: SEQ ID NO:44-46; SEQ ID NO:47-49; or SEQ ID NO:50-51 and 46, or an amino acid sequence having at least 70% identity or at most 3 mutated amino acid sequences compared to the above amino acid sequences; preferably, the HCDR1-3 and / or the LCDR1-3 are determined according to the Kabat, Chothia or IMGT method.

[0058] In some specific embodiments, the heavy chain variable region VH contains an amino acid sequence as shown in any one of SEQ ID NO:43 and 69-71, or an amino acid sequence having at least 70% identity or up to 15 mutations compared to the amino acid sequence.

[0059] In some specific embodiments, the antibody or antigen-binding fragment further comprises a heavy chain constant region CH and / or a light chain constant region CL; optionally, the heavy chain constant region and / or light chain constant region are selected from a complete constant region sequence or a fragment thereof, the constant region fragment including CH1, a hinge region, CH2, CH3, CL or Fc region; optionally, the heavy chain constant region is selected from human or mouse IgG1, IgG2, IgG3 or IgG4 constant regions, and the light chain constant region is selected from human or mouse kappa constant regions or lambda constant regions.

[0060] In some specific embodiments, the heavy chain constant region of the antibody or antigen-binding fragment has the amino acid sequence shown in SEQ ID NO:10.

[0061] In some specific implementations, the at least 70% identity is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity.

[0062] In some specific implementations, the maximum of 3 mutations is preferably 3, 2, 1 or 0 mutations.

[0063] In some specific implementations, the maximum 15 mutations can be up to 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 mutations.

[0064] Preferably, the mutation is selected from substitution, deletion or insertion mutations; preferably, the mutation is a reversion mutation or a hotspot mutation; preferably, the substitution is a conserved amino acid substitution.

[0065] In some specific embodiments, the antibody or antigen-binding fragments described in this disclosure include:

[0066] (1) a chimeric antibody or a fragment thereof; and / or

[0067] (2) Humanized antibodies or fragments thereof; and / or,

[0068] (3) Fully human antibodies or fragments thereof.

[0069] In some specific embodiments, the antibody or antigen-binding fragment is selected from monoclonal antibodies, polyclonal antibodies, natural antibodies, engineered antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, full-length antibodies, antibody fragments, naked antibodies, conjugated antibodies, humanized antibodies, fully human antibodies, Fab, Fab', F(ab)2, F(ab')2, Fd, Fv, scFv, diabody, or single-domain antibodies.

[0070] In some specific embodiments, the antibody or antigen-binding fragment specifically binds to LRRC15; preferably, the LRRC15 is human LRRC15, monkey LRRC15, and / or mouse LRRC15.

[0071] In some specific embodiments, the antibody or antigen-binding fragment exhibits one or more effector functions selected from the following: antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell phagocytosis (ADCP).

[0072] In some specific embodiments, the antibody or antigen-binding fragment is further coupled with a therapeutic agent or tracer; preferably, the therapeutic agent is selected from radioactive isotopes, chemotherapeutic agents or immunomodulators, and the tracer is preferably selected from radiographic contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents and photosensitizers.

[0073] In some specific embodiments, the antibody or antigen-binding fragment specifically binds to human LRRC15, monkey LRRC15, and / or mouse LRRC15. Preferably, the KD of the antibody or antigen-binding fragment binding to human LRRC15, monkey LRRC15, and / or mouse LRRC15 is less than 1E-6M, 1E-7M, 1E-8M, 1E-9M, 2E-9M, 3E-9M, 4E-9M, 5E-9M, 6E-9M, 7E-9M, 8E-9M, 9E-9M, 1E-10M, 2E-10M, 3E-10M, 4E-10M, 5E-10M, 6E-10M, 8E-10M, 9E-10M, or 1E-11M.

[0074] In a second aspect, this disclosure provides a multispecific antigen-binding molecule comprising the aforementioned antibody or antigen-binding fragment; and other antigen-binding molecules that bind antigens other than LRRC15, or other antigen-binding molecules that bind LRRC15 epitopes different from the aforementioned antibody or antigen-binding fragment; preferably, the other antigens are selected from tumor-specific antigens (TSA), tumor-associated antigens (TAA), immune checkpoints, and / or targets that recruit and / or activate immune cells.

[0075] Preferably, the other antigen-binding molecules are antibodies or antigen-binding fragments.

[0076] Preferably, the multispecific antigen-binding molecule may be bispecific, trispecific, or tetraspecific.

[0077] Preferably, the multispecific antigen-binding molecule may be bivalent, tetravalent, or hexavalent.

[0078] In a third aspect, this disclosure provides a chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises the aforementioned antibody or antigen-binding fragment.

[0079] In a fourth aspect, this disclosure provides an immune effector cell that expresses the aforementioned CAR or contains a nucleic acid fragment encoding the aforementioned CAR; preferably, the immune effector cell is selected from T cells, NK cells (natural killer cells), NKT cells (natural killer T cells), monocytes, macrophages, dendritic cells, or mast cells.

[0080] Preferably, the immune effector cells are autologous immune effector cells or allogeneic immune effector cells;

[0081] Preferably, the T cells are selected from cytotoxic T cells, regulatory T cells, or helper T cells.

[0082] In a fifth aspect, this disclosure provides an isolated nucleic acid molecule that encodes the aforementioned antibody or antigen-binding fragment, multispecific antigen-binding molecule, or chimeric antigen receptor.

[0083] In a sixth aspect, this disclosure provides a vector containing the aforementioned nucleic acid molecules.

[0084] In a seventh aspect, this disclosure provides a host cell containing the aforementioned nucleic acid molecules or the aforementioned vectors; preferably, the cell is a prokaryotic or eukaryotic cell, such as bacteria (Escherichia coli), fungi (yeast), insect cells, or mammalian cells (CHO cell line or 293T cell line); preferably, the cell lacks fucosyltransferase, such as FUT8.

[0085] In an eighth aspect, this disclosure provides a method for preparing the aforementioned antibody or antigen-binding fragment, or multispecific antigen-binding molecule, the method comprising culturing the aforementioned cells, and isolating the antibody or antigen-binding fragment expressed by the cells, or isolating the multispecific antigen-binding molecule expressed by the cells.

[0086] In a ninth aspect, this disclosure provides a method for preparing the aforementioned immune effector cells, the method comprising: introducing a nucleic acid molecule encoding the aforementioned CAR into the immune effector cells; optionally, the method further comprising initiating the expression of the aforementioned CAR in the immune effector cells.

[0087] In a tenth aspect, this disclosure provides a pharmaceutical composition comprising the aforementioned antibody or antigen-binding fragment, multispecific antigen-binding molecule, chimeric antigen receptor, immune effector cell, nucleic acid molecule, carrier, or cell; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent, or adjuvant; optionally, the pharmaceutical composition further comprises an additional therapeutic agent.

[0088] In the eleventh aspect, this disclosure provides the use of the aforementioned antibodies or antigen-binding fragments, multispecific antigen-binding molecules, chimeric antigen receptors, immune effector cells, nucleic acid molecules, carriers, or cells in the preparation of medicaments for treating tumors or cancer.

[0089] In a twelfth aspect, this disclosure provides a method for treating tumors or cancer, the method comprising administering to a subject an effective amount of the aforementioned antibody or antigen-binding fragment, multispecific antigen-binding molecule, chimeric antigen receptor, immune effector cell, nucleic acid molecule, carrier, or cell.

[0090] In the thirteenth aspect, this disclosure provides the aforementioned antibody or antigen-binding fragment, multispecific antigen-binding molecule, chimeric antigen receptor, immune effector cell, nucleic acid molecule, nucleic acid carrier or host cell for the treatment of tumors or cancer.

[0091] In aspects eleven to thirteen above, the tumor or cancer includes solid tumors; preferably, the tumor is a tumor expressing LRRC15.

[0092] In some implementations, the tumor or cancer may be selected from one or more of the following tumors or cancers, including but not limited to: lung cancer, pancreatic cancer, liver cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, gastric cancer, esophageal cancer, nasopharyngeal carcinoma, kidney cancer, cervical cancer, prostate cancer, bladder cancer, uterine cancer, melanoma, head and neck cancer, bile duct cancer, thyroid cancer, ovarian cancer, glioblastoma, or sarcoma.

[0093] In a fourteenth aspect, this disclosure provides a kit comprising the aforementioned antibody or antigen-binding fragment, multispecific antigen-binding molecule, immune effector cells, nucleic acid molecule, carrier, and product or pharmaceutical composition prepared according to the aforementioned method.

[0094] Terminology Definitions and Explanations

[0095] Unless otherwise defined in this disclosure, scientific and technical terms used in connection with this disclosure shall have the meanings understood by one of ordinary skill in the art.

[0096] Furthermore, unless otherwise stated herein, the terms used in this disclosure have the following meanings: the definitions of groups and terms recorded in this disclosure, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in the examples, etc., can be arbitrarily combined and combined with each other. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When trade names appear herein, they are intended to refer to the corresponding product or its active ingredient.

[0097] Furthermore, unless otherwise stated, singular terms herein shall include plural terms, and plural terms shall include singular terms. More specifically, as used in this specification and the appended claims, unless otherwise expressly indicated, the singular forms “a” and “this” include plural indicators.

[0098] The terms “comprising,” “including,” and “having” are used interchangeably herein to indicate the inclusiveness of a solution, meaning that the solution may contain elements other than those listed. It should also be understood that the use of “comprising,” “including,” and “having” herein also provides for solutions “composed of.” For example, “a composition comprising A and B” should be understood to include compositions consisting of A and B, as well as compositions containing other components besides A and B, both falling within the scope of the aforementioned “a composition.”

[0099] When used herein, the term “and / or” includes the meaning of “and,” “or,” and “all or any other combination of elements linked by the term.”

[0100] The term "LRRC15," also known as "HLib" or "LIB," is a member of the LRRC superfamily and is a type I transmembrane protein composed of 581 amino acids, consisting of a 15-leucine-rich repetitive sequence. "LRRC15" in this article includes the full-length LRRC15 protein or its mutants (e.g., point mutations, insertion mutations, or deletion mutations), splice variants, orthologs, and fragments of LRRC15. "LRRC15" in this article can be derived from humans, primates (e.g., cynomolgus monkeys, rhesus monkeys), and rodents (e.g., mice, rats). For example, the extracellular amino acid sequence of human LRRC15 can be found in UniProt ID: Q8TF66, the extracellular amino acid sequence of cynomolgus monkey LRRC15 can be found in UniProt ID: A0A2K5UKB6, and the extracellular amino acid sequence of mouse LRRC15 can be found in UniProt ID: Q80X72.

[0101] The terms "specific binding," "immunobinding," and "immunobinding properties" used in this article refer to a type of non-covalent interaction formed between an immunoglobulin molecule and an antigen to which the immunoglobulin has specificity. This type of interaction involves antigen-binding molecules (e.g., antibodies) typically binding to antigens with high affinity and substantially the same antigens, but not to unrelated antigens. The strength or affinity of an immunobinding interaction is typically reflected by the equilibrium dissociation constant (KD), where a lower KD indicates higher affinity. The immunobinding properties of a selected peptide can be quantitatively determined using methods well-known in the art. For example, with antibodies, high affinity typically refers to an affinity of approximately 10. -8 M or lower, approximately 1×10 -9 M or lower, approximately 1×10 -10 M or lower, 1×10 -11 M or lower KD. KD is calculated as follows: KD = Kd / Ka, where Kd represents the dissociation rate and Ka represents the binding rate. The equilibrium dissociation constant KD can be measured using methods known in the art, such as surface plasmon resonance (e.g., Biacore) or equilibrium dialysis.

[0102] The term "antigen-binding molecule" is used in the broadest sense in this document to refer to a molecule that specifically binds to an antigen. Exemplarily, antigen-binding molecules include, but are not limited to, antibodies or antibody mimics. "Antibody mimic" refers to an organic compound or binding domain that can specifically bind to an antigen but is independent of the antibody structure. Exemplarily, antibody mimics include, but are not limited to, affibody, affitin, affilin, designed ankylosing spondylamine repeat (DARPin), aptamers, or Kunitz-type domain peptides.

[0103] The term "antibody" as used in the broadest sense herein refers to a polypeptide or combination of polypeptides containing sufficient sequence from the variable region of the immunoglobulin heavy chain and / or sufficient sequence from the variable region of the immunoglobulin light chain to specifically bind to an antigen. The term "antibody" as used herein encompasses various forms and structures, provided they exhibit the desired antigen-binding activity. The terms "full-length antibody," "intact antibody," and "complete antibody" are used interchangeably herein and refer to a structure that is substantially similar to that of a natural antibody. The term "antibody" as used herein includes, but is not limited to, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, complete antibodies, fragments of complete antibodies, naked antibodies, conjugated antibodies, chimeric antibodies, humanized antibodies, or fully human antibodies.

[0104] The terms "antibody fragment" or "antigen-binding fragment" are used interchangeably herein to refer to a portion of an antibody that does not possess the full structure of a complete antibody, but only contains a local or local variant of the complete antibody, which has the ability to bind to the same antigen recognized by the complete antibody. "Antibody fragment" or "antigen-binding fragment" can be understood as a local or local variant of a complete antibody having the same antigenic determinant (CDR), a monoclonal antibody, a polyclonal antibody, a monospecific antibody, a multispecific antibody (e.g., a bispecific antibody), a monovalent antibody, a multivalent antibody, a complete antibody, a fragment of a complete antibody, a naked antibody, a conjugated antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.

[0105] "Antibody fragments" or "antigen-binding fragments" also include any synthetic or genetically engineered protein that functions like an antibody by binding to a specific antigen and forming a complex. For example, antibody fragments include isolated fragments consisting of light chain variable regions, "Fv" fragments consisting of heavy and light chain variable regions, recombinant single-chain polypeptide molecules (scFv) in which the light and heavy chain variable regions are linked by peptide linkers, and the smallest recognition unit consisting of amino acid residues mimicking hypervariable regions. The "antigen-binding fragments" or "antibody fragments" mentioned herein include, but are not limited to, Fab, F(ab)2, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody, and single-domain antibodies.

[0106] The term "antibody" in this article also includes alternative protein scaffolds or artificial scaffolds having a transplantable complementarity-determining region (CDR) or a CDR derivative. Such scaffolds include antibody-derived scaffolds (which contain mutations introduced to, for example, stabilize the three-dimensional structure of the antibody) and fully synthetic scaffolds containing, for example, biocompatible polymers. See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, 53(1):121-129 (2003); Roque et al., Biotechnol. Prog. 20:639-654 (2004). Such scaffolds may also include non-antibody-derived scaffolds, such as scaffold proteins known in the art for transplanting CDRs, including but not limited to tendinins, fibronectin, peptide aptamers, etc.

[0107] The term "antibody" in this article includes typical "quadruple-chain antibodies," which belong to immunoglobulins composed of two heavy chains (HC) and two light chains (LC). The heavy chain refers to a polypeptide chain consisting of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain in the N-to-C-terminal direction. Optionally, when the full-length antibody is an IgE isotype, it also includes a heavy chain constant region CH4 domain. The light chain is a polypeptide chain consisting of a light chain variable region (VL) and a light chain constant region (CL) in the N-to-C-terminal direction. Heavy chains are linked to each other and to each other with disulfide bonds, forming a "Y"-shaped structure. Because the amino acid composition and sequence of the immunoglobulin heavy chain constant region differ, their antigenicity also differs. Based on this, the "immunoglobulins" in this article can be divided into five classes, or isotypes of immunoglobulins: IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε chains, respectively. Within the same class of Ig, differences in the amino acid composition of the hinge region and the number and position of disulfide bonds in the heavy chain can further lead to different subclasses. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4, and IgA into IgA1 and IgA2. Light chains are classified as κ or λ chains based on differences in their constant regions. Each of the five classes of Ig can possess either a κ or λ chain.

[0108] The term "antibody" in this article also includes antibodies that do not contain light chains, such as heavy-chain antibodies (HCAbs) produced by camels (Camelus dromedarius), Bactrian camels (Camelus bactrianus), llamas (Lama glama), guanicoes (Lama guanicoe), and alpacas (Vicugna pacos), as well as immunoglobulin new antigen receptors (IgNARs) found in cartilaginous fish such as sharks.

[0109] Papain digestion of the intact antibody produces two identical antigen-binding fragments, called “Fab” fragments, each containing variable domains for both the heavy and light chains, as well as a constant domain for the light chain and a first constant domain (CH1) for the heavy chain. Thus, the term “Fab fragment” as used herein refers to the antibody fragment containing the VL domain and constant domain (CL) of the light chain, and the VH domain and first constant domain (CH1) of the heavy chain. The Fab’ fragment differs from the Fab fragment by the addition of a few residues at the carboxyl terminus of the CH1 domain of the heavy chain, including one or more cysteine ​​residues from the antibody hinge region. Fab’-SH is the Fab’ fragment in which the cysteine ​​residues in the constant domain carry a free thiol group. Pepsin treatment produces the F(ab’)2 fragment, which has two antigen-binding sites (two Fab fragments) and a portion of the Fc region.

[0110] The term "Fd" in this paper refers to an antibody composed of VH and CH1 domains. The term "Fv" refers to an antibody fragment composed of a single-arm VL and VH domain. Fv fragments are generally considered to be the smallest antibody fragment capable of forming a complete antigen-binding site. Fv fragments possess the same binding properties and similar three-dimensional binding characteristics as Fab fragments. The VH and VL chains of an Fv fragment are linked together through non-covalent interactions. It is generally believed that six CDRs confer antigen-binding specificity to the antibody. However, even a variable region (e.g., an Fd fragment containing only three antigen-specific CDRs) can recognize and bind to antigens, although its affinity may be lower than that of a complete binding site.

[0111] The term "scFv" (single-chain variable fragment) in this document refers to a single polypeptide chain containing VL and VH domains linked together by a linker. Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of a repeating GGGGS (SEQ ID NO:91) amino acid sequence or a variant thereof. For example, a linker having the amino acid sequence (GGGGS)4 (SEQ ID NO:92) may be used, but variants thereof may also be used. Other linkers that can be used in this disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol. In some cases, a disulfide bond may also exist between the VH and VL of scFv, forming a disulfide-linked Fv (dsFv).

[0112] The term "diabody" in this article refers to a single polypeptide chain in which the VH and VL domains are expressed, but the linker is too short to allow pairing between the two domains on the same chain, thus forcing the domain to pair with the complementary domain of another chain and creating two antigen-binding sites.

[0113] The term "heavy chain antibody" in this article refers to an antibody that lacks a light chain, as is commonly used in antibody therapy. This term specifically includes, but is not limited to, homodimeric antibodies that contain a VH antigen-binding domain and constant CH2 and CH3 domains in the absence of a CH1 domain.

[0114] The terms "single domain antibody" (sdAb), "VHH," and "nanobody" used in this article have the same meaning and are used interchangeably. They refer to the cloning of the variable region of an antibody heavy chain to construct a single-domain antibody consisting of only one heavy chain variable region. It is the smallest antigen-binding fragment with complete function. Typically, antibodies lacking both the light chain and the heavy chain constant region 1 (CH1) are first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody consisting of only one heavy chain variable region. Single-domain antibodies can be derived from camel heavy chain antibodies or chondrogenic fish IgNARs.

[0115] The term "chimeric antibody" in this document refers to an antibody whose light chain and / or heavy chain is derived from a portion of an antibody (which may be derived from a specific species or belong to a specific antibody class or subclass), and another portion of the light chain and / or heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but which retains its binding activity to the target antigen. For example, the term "chimeric antibody" can include antibodies (e.g., human-mouse chimeric antibodies) in which the variable regions of the heavy and light chains of the antibody are derived from a first antibody (e.g., a mouse antibody), while the constant regions of the heavy and light chains of the antibody are derived from a second antibody (e.g., a human antibody).

[0116] The term "humanized antibody" in this article refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase its homology with that of a human antibody. Typically, all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), while all or part of the non-CDR region (e.g., the FR and / or constant regions within the variable region) is derived from a human immunoglobulin (receptor antibody). Humanized antibodies generally retain or partially retain the intended properties of the donor antibody, including but not limited to antigen specificity, affinity, reactivity, the ability to enhance immune cell activity, and the ability to strengthen the immune response.

[0117] The term "fully human antibody" as used herein refers to an antibody having variable regions in which both the FR and CDR are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, that constant region is also derived from a human germline immunoglobulin sequence. "Fully human antibody" as used herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced through random or site-specific mutagenesis in vitro or through somatic mutations in vivo). However, "fully human antibody" as used herein does not include antibodies in which a CDR sequence derived from another mammalian species (e.g., mouse) has been grafted onto a human frame sequence.

[0118] The term "naked antibody" as used herein refers to an antibody that is not linked, fused to, or conjugated with another agent or molecule (e.g., a label or drug), peptide, or polypeptide. In specific embodiments, naked antibodies expressed by mammalian host cells may be glycosylated by the host cell's glycosylation machinery (e.g., glycosylation enzymes). In some embodiments, naked antibodies are not glycosylated when expressed by host cells that do not possess their own glycosylation machinery (e.g., glycosylation enzymes). In some embodiments, naked antibodies are intact antibodies, while in other embodiments, naked antibodies are antigen-binding fragments of intact antibodies.

[0119] The “antibody” in this article can be derived from any animal, including but not limited to humans and non-human animals. The non-human animals can be selected from primates, mammals, rodents and vertebrates, such as camels, llamas, guanacos, alpacas, sheep, rabbits, mice, rats or cartilaginous fish (e.g., sharks).

[0120] The term "monoclonal antibody" as used herein refers to an antibody derived from a substantially homogeneous population of antibodies, meaning that, apart from possible variants (e.g., containing naturally occurring mutations or generated during the manufacturing process of the formulation, such variants are typically present in small amounts), the individual antibodies comprising this population are identical and / or bind to the same epitopes. In contrast to polyclonal antibody formulations, which typically comprise different antibodies targeting different determinants (epitaxes), each monoclonal antibody in a monoclonal antibody formulation targets a single determinant on the antigen. The modifier "monoclonal" herein should not be construed as requiring the production of the antibody or antigen-binding molecule by any particular method. For example, monoclonal antibodies can be produced using a variety of techniques, including (but not limited to) hybridoma techniques, recombinant DNA methods, phage library display techniques, methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, and other methods known in the art.

[0121] The term "natural antibody" in this article refers to antibodies produced and paired by the immune system of multicellular organisms. The term "engineered antibody" in this article refers to non-natural antibodies obtained through techniques such as genetic engineering and antibody engineering. For example, "engineered antibodies" include chimeric antibodies, humanized antibodies, antibody fragments (such as scFv, sdAb, etc.), bispecific antibodies, etc.

[0122] The term "monospecific" refers to having one or more binding sites, where each binding site binds to the same epitope of the same antigen.

[0123] The term "multispecific antibody" refers to an antibody having at least two antigen-binding sites, each of which binds to a different epitope of the same antigen or to a different epitope of a different antigen. Therefore, terms such as "bispecific," "trispecific," and "quadrispecific" refer to the number of different epitopes that an antibody / antigen binding molecule can bind to.

[0124] The term "valence" indicates the number of binding sites present in an antibody / antigen binding molecule. Therefore, the terms "monovalent," "divalent," "tetravalent," and "hexavalent" indicate the presence of one, two, four, and six binding sites in an antibody / antigen binding molecule, respectively.

[0125] The term "variable region" in this article refers to the region in the antibody heavy or light chain involved in antibody binding to the antigen. "Heavy chain variable region" is interchangeable with "VH" and "HCVR," and "light chain variable region" is interchangeable with "VL" and "LCVR." The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies generally have similar structures, with each domain containing four conserved framework regions (FRs) and three hypervariable regions (HVRs). A single VH or VL domain is sufficient to confer antigen binding specificity. The term "complementarity-determining region" is interchangeable with "CDR" in this article, and usually refers to the hypervariable region (HVR) of the heavy chain variable region (VH) or light chain variable region (VL). This region is called the complementarity-determining region because it can form precise complementarity with the antigen epitope in its spatial structure. The heavy chain variable region CDR can be abbreviated as HCDR, and the light chain variable region CDR can be abbreviated as LCDR. The terms "framework region" and "FR region" are interchangeable, referring to the amino acid residues in the antibody heavy or light chain variable region other than the CDR. Typically, the variable region of an antibody consists of four FR regions and three CDR regions in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0126] The term "CDR" in this paper may be labeled and defined in a manner known in the art, including but not limited to the Kabat numbering system, the Chothia numbering system, or the IMGT numbering system. The tools and websites used include, but are not limited to, the AbRSA website (http: / / cao.labshare.cn / AbRSA / cdrs.php), the abysis website (www.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi), and the IMGT website (http: / / www.imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi#results). The CDR in this paper includes overlaps and subsets of amino acid residues defined in different ways.

[0127] The term "Kabat numbering system" in this article usually refers to the immunoglobulin alignment and numbering system proposed by Elvin A. Kabat (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).

[0128] The term “Chothia numbering system” in this article usually refers to the immunoglobulin numbering system proposed by Chothia et al., which is a classic rule for identifying the boundaries of CDR regions based on the location of structural loop regions (see, for example, Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883).

[0129] The term "IMGT numbering system" in this article generally refers to the numbering system based on the international ImMunoGeneTics information system (IMGT) initiated by Lefranc et al., see Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003.

[0130] The term "heavy chain constant region" in this document refers to the carboxyl-terminal portion of the antibody heavy chain, which does not directly participate in antibody-antigen binding but exhibits effector functions, such as interaction with the Fc receptor, and has a more conserved amino acid sequence relative to the variable domains of the antibody. A "heavy chain constant region" comprises at least: a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, or variants or fragments thereof. "Heavy chain constant region" includes "full-length heavy chain constant region" and "heavy chain constant region fragments," the former having a structure substantially similar to the natural antibody constant region, while the latter comprises only a portion of the full-length heavy chain constant region. Exemplarily, a typical "full-length antibody heavy chain constant region" consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is IgE, it also includes a CH4 domain; when the antibody is a heavy chain antibody, it does not include the CH1 domain. Exemplarily, a typical "heavy chain constant region fragment" may be selected from the CH1, Fc, or CH3 domains.

[0131] The term "light chain constant region" in this article refers to the carboxyl terminus of the antibody light chain, which does not directly participate in the binding of the antibody to the antigen. The light chain constant region can be selected from the constant κ domain or the constant λ domain.

[0132] The term "Fc" in this document refers to the carboxyl-terminal portion of an antibody obtained by papain hydrolysis of an intact antibody, typically containing the CH3 and CH2 domains of the antibody. Fc regions include, for example, native sequence Fc regions, recombinant Fc regions, and variant Fc regions. Although the boundaries of the Fc region of the immunoglobulin heavy chain can vary slightly, the Fc region of the human IgG heavy chain is generally defined as extending from the amino acid residue at Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine (residue 447 according to the Kabat numbering system) of the Fc region can be removed, for example, during antibody production or purification, or by recombinant engineering of the nucleic acid encoding the antibody heavy chain; therefore, the Fc region may or may not include the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447).

[0133] The term "epitope" in this document refers to any protein determinant capable of specifically binding to immunoglobulins, scFv, or T-cell receptors. Epitope determinants typically consist of chemically active surface clusters of molecules such as amino acid or sugar side chains, and usually possess specific three-dimensional structural features and specific charge characteristics. For example, antibodies can target the N-terminus or C-terminus of a polypeptide.

[0134] The term "mutation" in this article includes gene mutations and amino acid mutations. Gene mutations refer to deletions, insertions, inversions, or substitutions of heterologous nucleic acids, which may lead to changes in the amino acid sequence of the corresponding protein product. Amino acid mutations, also known as nonsynonymous single nucleotide mutations, are caused by changes in a few single bases, resulting in changes in the amino acid sequence of the protein product. Changes in amino acids can affect protein stability, interactions, and enzyme activity, thereby leading to disease.

[0135] The term "amino acid (aa)" in this article refers to the basic building blocks of proteins, giving them their specific molecular structure and biochemical activity. In chemistry, amino acids are organic compounds containing both an amino group (-NH₂) and a carboxyl group (-COOH). Based on the position of the amino group attached to a carbon atom in a carboxylic acid, amino acids are classified as α, β, γ, δ, etc.: in α-amino acids, the amino and carboxyl groups are attached to the same carbon atom; in β-amino acids, they are attached to adjacent carbon atoms, and so on. In biology, the term "amino acid" usually specifically refers to α-amino acids, where the amino and carboxyl groups are directly attached to the same -CH- structure, with the general formula H₂NCHRCOOH (where R represents an organic substituent). For example, the 20 common amino acids include glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartate, histidine, asparagine, glutamate, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, and proline.

[0136] The term "amino acid substitution" in this article refers to the removal of at least one amino acid residue from the natural or starting sequence, and the insertion of different amino acids at the same position. Substitutions can be single, where only one amino acid in the molecule is substituted, or they can be multiple, where two or more amino acids in the same molecule are substituted.

[0137] The term "conservative amino acid substitution" in this document refers to the substitution of an amino acid normally present in a sequence with a different amino acid having similar size, charge, or polarity. Examples of conservative substitution include replacing a nonpolar (hydrophobic) residue such as isoleucine, valine, and leucine with another nonpolar residue. Similarly, examples of conservative substitution include replacing a polar (hydrophilic) residue with another residue, such as between arginine and lysine, between glutamine and asparagine, and between glycine and serine. Additionally, replacing a basic residue such as lysine, arginine, or histidine with another residue, or replacing an acidic residue such as aspartic acid or glutamic acid with another acidic residue, are additional examples of conservative substitution. Examples of nonconservative substitution include replacing a nonpolar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, or methionine with a polar (hydrophilic) residue such as cysteine, glutamine, glutamic acid, or lysine, and / or replacing a polar residue with a nonpolar residue.

[0138] The term "mutant" in this document refers to a "variant" of the protein or peptide that has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% amino acid identity with the amino acid sequence of the protein or peptide.

[0139] The term "nucleic acid" in this document includes any compound and / or substance comprising a polymer containing nucleotides. Each nucleotide consists of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Typically, nucleic acid molecules are described by the sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule. The sequence of bases is typically represented as 5′ to 3′. In this document, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, for example, complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), particularly messenger RNA (mRNA), synthetic forms of DNA or RNA, and polymers containing mixtures of two or more of these molecules. Nucleic acid molecules can be linear or circular. Furthermore, the term nucleic acid molecule includes both sense and antisense strands, as well as single-stranded and double-stranded forms. Moreover, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases having derived sugar or phosphate backbones or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as carriers for the direct expression of the antibodies disclosed herein in vitro and / or in vivo, such as in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) carriers can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA carrier and / or the expression of the encoded molecule, thereby allowing the mRNA to be injected into a subject to generate antibodies in vivo.

[0140] The term "identity" in this document can be calculated as follows: To determine the percentage of "identity" between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., vacancies may be introduced in one or both of the first and second amino acid sequences or nucleic acid sequences for optimal alignment, or non-homologous sequences may be discarded for comparison purposes). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. The molecules are identical at that position when a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence.

[0141] Taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap, the percentage of identity between the two sequences varies with the common positions shared by the sequences.

[0142] Mathematical algorithms can be used to compare sequences and calculate the percentage of identity between two sequences. For example, the Needleman and Wunsch ((1970) J. Mol. Biol. 48: 444-453) algorithm (available at www.gcg.com) in the GAP program integrated into the GCG software package can be used to determine the percentage of identity between two amino acid sequences using a Blosum 62 matrix or a PAM250 matrix and vacancy weights of 16, 14, 12, 10, 8, 6, or 4 and length weights of 1, 2, 3, 4, 5, or 6. As another example, the GAP program in the GCG software package (available at www.gcg.com) can be used to determine the percentage of identity between two nucleotide sequences using an NWSgapdna.CMP matrix and vacancy weights of 40, 50, 60, 70, or 80 and length weights of 1, 2, 3, 4, 5, or 6. The particularly preferred set of parameters (and unless otherwise specified, a set of parameters to be used) is a Blosum62 scoring matrix with a vacancy penalty of 12, a vacancy extension penalty of 4, and a shift vacancy penalty of 5.

[0143] The PAM120 weighted remainder table, a gap length penalty of 12, and a gap penalty of 4 can be used to determine the percentage of identity between two amino acid sequences or nucleotide sequences using the E. Meyers and W. Miller algorithm ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0).

[0144] Additionally or alternatively, the nucleic acid and protein sequences described in this disclosure can be further used as “query sequences” to perform searches against public databases to, for example, identify sequences of other family members or related sequences. For example, such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul et al., (1990) J.Mol.Biol.215:403-10. BLAST nucleotide searches can be performed using the NBLAST program. BLAST protein searches can be performed using the XBLAST program to obtain amino acid sequences homologous to the protein molecules of this disclosure. To obtain alignment results with vacancies for comparative purposes, vacancy BLAST can be used as described in Altschul et al., (1997) Nucleic Acids Res.25:3389-3402. When using BLAST and vacancy BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See www.ncbi.nlm.nih.gov.

[0145] The term "chimeric antigen receptor (CAR)" in this article refers to an artificial cell surface receptor modified to be expressed on immune effector cells and specifically bind to antigens, comprising at least (1) an extracellular antigen-binding domain, such as a variable heavy or light chain of an antibody, (2) a transmembrane domain that anchors the CAR to enter immune effector cells, and (3) an intracellular signal transduction domain. CARs can redirect T cells and other immune effector cells to selected targets, such as cancer cells, in a non-MHC-restricted manner using the extracellular antigen-binding domain.

[0146] As used herein, the term "vector" includes nucleic acid vectors, such as DNA vectors (e.g., plasmids), RNA vectors, viruses, or other suitable replicons (e.g., viral vectors). Various vectors have been developed for delivering polynucleotides encoding foreign proteins into prokaryotic or eukaryotic cells. The expression vectors of this disclosure contain polynucleotide sequences and additional sequence elements, for example, for expressing proteins and / or integrating these polynucleotide sequences into the genome of mammalian cells. Some vectors that can be used to express the antibodies and antibody fragments of this disclosure include plasmids containing regulatory sequences (e.g., promoter and enhancer regions) that guide gene transcription. Other useful vectors for expressing antibodies and antibody fragments contain polynucleotide sequences that enhance the translation rate of these genes or improve the stability or nuclear export of mRNA produced by gene transcription. These sequence elements include, for example, 5' and 3' untranslated regions, internal ribosome entry sites (IRES), and polyadenylation signal sites to guide efficient transcription of the gene carried on the expression vector. The expression vectors of this disclosure may also contain polynucleotides encoding markers for selecting cells containing such vectors. Examples of suitable markers include genes encoding resistance to antibiotics such as ampicillin, chloramphenicol, kanamycin, or norsocrine.

[0147] The term "host cell" in this article refers to a cell in which foreign nucleic acids have been introduced, including the progeny of such cells. Host cells include "transformers" and "transformed cells," which include primary transformed cells and their progeny, regardless of the number of passages. Progeny may not be identical to parental cells in their nucleic acid contents and may contain mutations. This article includes mutant progeny with the same function or biological activity as those screened or selected in the initially transformed cells.

[0148] The term "pharmaceutical composition" herein refers to a formulation which is present in a form that allows for the biological activity of the active ingredient contained therein and does not contain any additional ingredients that would have unacceptable toxicity to a subject administered the pharmaceutical composition. The purpose of the pharmaceutical composition is to facilitate the administration of the antibodies of this disclosure to an organism.

[0149] The terms "pharmaceuticalally acceptable excipient," "pharmaceuticalally acceptable carrier," or "pharmaceuticalally acceptable carrier, diluent, or adjuvant" used herein refer to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art and include, for example, carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0150] The term "treatment" in this article refers to surgical or therapeutic treatment aimed at preventing, slowing (reducing) the progression of undesirable physiological changes or lesions in the treated individual, such as tumors or cancers, autoimmune diseases, and viral infections. Beneficial or desired clinical outcomes include, but are not limited to, symptom relief, disease severity reduction, disease stability (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of disease status, and remission (whether partial or complete), whether detectable or undetectable. Individuals requiring treatment include those already suffering from the condition or disease, those susceptible to the condition or disease, or those intending to prevent the condition or disease. When the terms slowing, reducing, weakening, mitigating, or alleviating are used, they also include elimination, disappearance, and non-occurrence.

[0151] The terms “subject,” “object,” and “patient” in this document refer to an organism receiving treatment for a specific disease or condition as described in this disclosure. Examples of objects and patients include mammals, such as humans, primates (e.g., monkeys), or non-primate mammals receiving treatment for a disease or condition. “Patient” also refers to an organism receiving treatment for a specific disease or condition (such as a tumor or cancer) as described herein.

[0152] The term "effective dose" in this document refers to the amount of a therapeutic agent, when administered alone or in combination with another therapeutic agent to cells, tissues, or subjects, that is effective in preventing or alleviating symptoms of a disease or the progression of that disease. "Effective dose" also refers to the amount of a compound sufficient to relieve symptoms, such as treating, curing, preventing, or alleviating an associated medical condition, or increasing the rate at which such symptoms are treated, cured, prevented, or alleviated. When an active ingredient is administered to an individual alone, the therapeutically effective dose refers to that ingredient alone. When a combination is used, the therapeutically effective dose refers to the combined amount of active ingredients that produce a therapeutic effect, regardless of whether they are administered in combination, consecutively, or simultaneously.

[0153] The amount of the antibody constituting a “therapeutic effective amount” of this disclosure varies depending on the antibody, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but may routinely be determined by a person skilled in the art based on their own knowledge and the content of this disclosure.

[0154] The term "tumor" or "tumor" in this document refers to all neoplasmic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The term "cancer" in this document refers to or describes a physiological condition typically characterized by unregulated cell growth in mammals. This definition includes both benign and malignant cancers. The terms "cancer" and "tumor" are not mutually exclusive when used herein. Exemplarily, tumors or cancers described in this disclosure include, but are not limited to, solid tumors such as lung cancer, pancreatic cancer, liver cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, gastric cancer, esophageal cancer, nasopharyngeal carcinoma, kidney cancer, cervical cancer, prostate cancer, bladder cancer, uterine cancer, melanoma, head and neck cancer, bile duct cancer, thyroid cancer, ovarian cancer, glioblastoma, or sarcoma. Attached Figure Description

[0155] Figure 1 shows the binding activity of A) CHI-01 and its humanized antibody molecules with endogenous U-118MG cells; B) CHI-02 and its humanized antibody molecules with endogenous U-118MG cells; C) CHI-03 and its humanized antibody molecules with endogenous U-118MG cells; and D) M25 and its humanized antibody molecules with endogenous U-118MG cells.

[0156] Figure 2 shows the binding activity of A) CHI-01 and its humanized antibody molecules with 293T-huLRRC15 cells; B) CHI-02 and its humanized antibody molecules with 293T-huLRRC15 cells; C) CHI-03 and its humanized antibody molecules with 293T-huLRRC15 cells; and D) M25 and its humanized antibody molecules with 293T-huLRRC15 cells. Detailed Implementation

[0157] The present disclosure will be further described below with reference to specific embodiments, and the advantages and features of the present disclosure will become clearer with the description. Unless otherwise specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments used, unless otherwise specified, are all commercially available conventional products.

[0158] The embodiments disclosed herein are merely exemplary and do not constitute any limitation on the scope of this disclosure. Those skilled in the art should understand that modifications or substitutions to the details and form of the technical solutions disclosed herein can be made without departing from the spirit and scope of this disclosure, but all such modifications and substitutions fall within the protection scope of this disclosure.

[0159] Example 1: Preparation of control antibody, antigen, and LRRC15 overexpressing cell line

[0160] 1.1 Preparation of control antibodies

[0161] The amino acid sequences of the anti-human LRRC15 monoclonal antibody Samrotamab (antibody sequence source: US10188660B2; where the VH and VL sequences are shown in SEQ ID NO:1-2 in Table 1, and the heavy / light chain constant region sequences are shown in SEQ ID NO:5 and 7 in Table 1, respectively) and the anti-FITC isotype control antibody (VH and VL sequences are shown in SEQ ID NO:3-4 in Table 1; the heavy / light chain constant region sequences are shown in SEQ ID NO:6 and 7 in Table 1, respectively) were cloned into the pTT5 vector (Ubibio, catalog number: VT2202) and plasmids were prepared according to standard molecular biology methods established in the art. The expression vector and transfection reagent PEI (Polysciences, 24765-1) were added to OPTI-MEM (Gibco, catalog number: 11058021), mixed well, and incubated for 15 min. This mixture was then added to Expi293F cells (Thermofisher, A14527) and cultured in a shaker at 37°C with 5% CO2 at 120 rpm. On the second day after transfection, OPM-293ProFeed (Shanghai OPMI, F081918-001) and 6 g / L glucose (Sigma, G7528) were added. On the sixth day after transfection, the cell supernatant was collected. The culture supernatant was loaded onto a protein A chromatography column (AT Protein A Diamond packing material and BXK16 / 26 column, both purchased from BorgL). The column was washed with PBS phosphate buffer (pH 7.4), followed by washing with 20 mM PB, 1 M NaCl, pH 7.2, and finally eluted with citrate buffer (pH 3.4). The antibody eluted from the protein A column was collected, neutralized with 1 / 10 volume of 1 M Tris (pH 8.0), and dialyzed overnight with PBS at 4°C. The antibody concentration was determined using Nanodrop, and antibody purity was determined using HPLC-SEC. The endotoxin content of the antibody was detected using an endotoxin detection kit (purchased from Andros). Finally, the control antibody was aseptically filtered through 0.22 μm and aliquoted, then stored at -80°C.

[0162] Table 1: Sequence information of anti-human LRRC15 antibody Samrotamab and isotype control antibody

[0163] 1.2 Preparation of Antigen

[0164] The amino acid sequence of the extracellular domain (ECD) of human LRRC15 protein (UniProt ID: Q8TF66, SEQ ID NO: 8 in Table 2), the amino acid sequence of the extracellular domain of cynomolgus monkey LRRC15 protein (UniProt ID: A0A2K5UKB6, SEQ ID NO: 11 in Table 2), and the amino acid sequence of the extracellular domain of mouse LRRC15 protein (UniProt ID: Q80X72, SEQ ID NO: 12 in Table 2) were coupled with hFc (human IgG1Fc fragment, SEQ ID NO: 10 in Table 2) or mFc (mouse IgG2aFc fragment, SEQ ID NO: 9 in Table 2) or a 6*histidine tag and cloned into the pTT5 vector (Ubibio, catalog number: VT2202). For plasmid construction, antigen expression, and purification methods, please refer to the preparation process of control antibodies in 1.1 to obtain antigen proteins such as human / monkey / mouse LRRC15-mFc, human / monkey / mouse LRRC15-hFc, and human / monkey / mouse LRRC15-His.

[0165] Table 2: Extracellular sequence of LRRC15 protein Note: The underlined part is the signal peptide.

[0166] 1.3 Preparation of LRRC15 overexpressing cell lines

[0167] 1.3.1 Construction of CHO-K1 overexpressing human LRRC15 engineered cell line

[0168] The nucleotide sequence encoding the full-length amino acid sequence of human LRRC15 (UniProt ID: Q8TF66) was cloned into the pLVX-IRES-Puro vector (purchased from Ubisoft Biotechnology, catalog number: VT1464), packaged as a lentivirus, and subsequently used to infect CHO-K1 cells (purchased from the Chinese Academy of Sciences). Seventy-two hours after viral infection, CHO-K1 cells were analyzed by flow cytometry using the known LRRC15 antibody Samrotamab (prepared in Example 1.1). Once transfected cells were confirmed to express huLRRC15 protein, they were screened in DMEM / F12 medium (Gibco, catalog number 12634028) containing 10 μg / ml puromycin (Gibco, catalog number A1113802) and 10% (w / w) fetal bovine serum (Gibco, catalog number 110099-141C). After cell recovery, subcloning was performed using limiting dilution in 96-well plates, and the cells were cultured at 37°C in a 5% (v / v) CO2 incubator. After approximately two weeks, a selection of single-clone wells were amplified. The amplified clones were then screened using Samrotamab antibody via flow cytometry. Cell lines with good growth and high fluorescence intensity were selected for further expansion, re-analyzed by flow cytometry, and then cryopreserved in liquid nitrogen to obtain the stable transfected cell line CHO-K1-huLRRC15, which highly expresses huLRRC15.

[0169] 1.3.2 Construction of 293T engineered cell line overexpressing human LRRC15

[0170] The nucleotide sequence encoding the full-length amino acid sequence of human LRRC15 (UniProt ID: Q8TF66) was cloned into the pLVX-IRES-Puro vector (purchased from Ubisoft Biotechnology, catalog number: VT1464), packaged as a lentivirus, and subsequently used to infect 293T cells (purchased from the Chinese Academy of Sciences). 72 hours after viral infection, 293T cells were detected by flow cytometry using the known LRRC15 antibody Samrotamab (prepared in Example 1.1). Once transfected cells were confirmed to express huLRRC15 protein, they were screened in DMEM (purchased from Gibco, catalog number: 11995-065) containing 2 μg / ml puromycin (purchased from Gibco, catalog number: A1113802) and 10% (w / w) fetal bovine serum (purchased from Gibco, catalog number: 110099-141C). After cell recovery, the cells were again detected by flow cytometry using the Samrotamab antibody. Then, the culture was expanded, and the cells were re-tested by flow cytometry and frozen in liquid nitrogen to obtain a stable cell line 293T-huLRRC15 that highly expresses huLRRC15.

[0171] 1.3.3 Construction of Flp-In-CHO overexpressing monkey LRRC15 engineered cell line

[0172] The nucleotide sequence encoding the full-length amino acid sequence of LRRC15 in cynomolgus monkeys (UniProt ID: A0A2K5UKB6) was cloned into the pcDNA5 vector (purchased from Ubisoft Biotechnology, catalog number: VT2202) and a plasmid was prepared. The plasmid was then transfected into the Flp-In-CHO cell line (purchased from Thermo). The 3000 Transfection Kit (Invitrogen, catalog number: L3000-015) was used. Forty-eight hours after transfection, the cells were analyzed by flow cytometry using the known LRRC15 antibody Samrotamab (prepared in Example 1.1). Once transfected cells were confirmed to express cynoLRRC15 protein, they were screened in F12 medium (Gibco, catalog number: 11765-054) containing 800 μg / ml hygromycin (Invitrogen, catalog number: 10687010) and 10% (w / w) fetal bovine serum (Gibco, catalog number: 110099-141C). After cell recovery, the cells were again analyzed by flow cytometry using the Samrotamab antibody. The cells were then expanded, re-analyzed by flow cytometry, and then cryopreserved in liquid nitrogen to obtain the stable cynoLRRC15 cell line FlpinCHO-cynoLRRC15, which highly expresses cynoLRRC15.

[0173] Example 2: Preparation of anti-human LRRC15 murine monoclonal antibody

[0174] 2.1 Mouse immunization and serum titer detection

[0175] The experimental animals used in the animal immunization experiments were 6-8 week old female SJL and Balb / c mice (purchased from Shanghai Silex Co., Ltd.), housed in SPF-grade environments. The immunogens were CHO-K1-hLRRC15 cells (prepared in Example 1.3), human LRRC15-mFc protein, and mouse LRRC15-mFc protein (both prepared in Example 1.2). Blood was collected from the orbital sinus of mice before immunization to obtain negative serum. For the initial immunization, 0.1 mL of TiterMax (Sigma, T2684) emulsified with physiological saline was injected intraperitoneally. Fifteen minutes later, 0.1 mL of a CHOK1-hLRRC15 cell and CpG (synthesized by Sangon Biotech, catalog number: ODN1826) suspension was injected intraperitoneally, resulting in 1E7 cells per mouse. Booster immunizations were performed weekly thereafter. For the 2nd-4th immunizations, 1E7 cells were injected intraperitoneally. For the 3rd immunization, 0.1 mL of emulsified TiterMax was injected first. The 5th and 6th immunizations used mouse LRRC-15-mFc antigen (prepared in Example 1.2). The antigen was emulsified with Alum (Thermo, 77161) and CpG (synthesized by Sangon Biotech, catalog number: ODN1826) and administered intraperitoneally (0.1 ml). It was also emulsified with TiterMax (Sigma, T2684) and CpG and administered subcutaneously and via multiple injections to the plantar surface, resulting in a total injection of 25 μg of immunogen per mouse. The 7th immunization used both mouse LRRC-15-mFc antigen and human LRRC15-mFc antigen (prepared in Example 1.2), administered using the same method as above.

[0176] Blood samples were collected from the orbital sinuses of mice 5 days after the 3rd, 5th, and 7th immunizations. The binding titer of antibodies in mouse serum to human LRRC15-hFC protein (prepared in Example 1.2) was determined using enzyme-linked immunosorbent assay (ELISA). After dilution 72.9K times, the immunized mouse serum in all groups still showed a positive antigen-antibody reaction (OD value greater than 1), indicating that the antibodies in the mouse serum bound well to the immunogen.

[0177] 2.2 Spleen cell fusion and hybridoma screening

[0178] Spleen cell fusion was performed on mice with high antibody titers in their serum. Three days prior to fusion, a final booster immunization was administered via subcutaneous, plantar, and intraperitoneal injection of 50 μg / mouse of mouse LRRC-15-mFc antigen solution prepared with physiological saline. After euthanasia, the spleen and lymph nodes were aseptically harvested, ground, and filtered through a 40-micron cell filter (BD Falcon) to collect the spleen and lymphocyte suspensions. Centrifugation was performed at 1500 rpm for 5 min, and the supernatant was discarded. Cells were washed once at 1500 rpm with DMEM basal medium (Gibco, 10569044), and then mixed with mouse myeloma cells SP2 / 0 (ATCC, Cat. CRL-1581) at a live cell ratio of 2:1. Cell fusion was performed using the BTX ECM2001+ high-efficiency electrofusion method (see METHODS IN ENZYMOLOGY, VOL. 220). The fused cells were diluted in DMEM medium containing 20% ​​(w / w) fetal bovine serum (ExCell Bio, FSD500), 1×HAT (Gibco, 21060017), bovine insulin (Yeason, 40107ES25), and NEAA (Gibco, 11140050), and then diluted at 5×10⁻⁶ ppm. 4 Add 200 μL of cells per well to a 96-well cell culture plate and incubate in a 5% (v / v) CO2 incubator at 37°C.

[0179] Seven days later, the supernatant from the fusion plate was screened using ELISA to determine its binding activity to mouse LRRC15 protein. Supernatants from positive clones with high binding activity were selected, and their binding activity to human LRRC15 protein and cells overexpressing human LRRC15 was further determined using ELISA. Based on the screening results, qualified positive clones were selected and subcloned using semi-solid medium (Stemcell, Cat. 03810). Seven days later, the grown clones were individually transferred to 96-well plates and expanded in DMEM medium containing 10% (w / w) fetal bovine serum and 1×HT (Gibco, 11067030). One day later, preliminary screening was performed using ELISA, and single clones with positive binding activity to both human and mouse LRRC15 protein were amplified and cultured in 24-well plates. Three days later, the culture supernatant was further analyzed to evaluate its binding activity to human LRRC15 protein and cells, and mouse LRRC15 protein and cells.

[0180] Based on the test results of the 24-well plate samples, the optimal clone was selected and cultured in DMEM medium containing 10% FBS at 37°C and 5% CO2. After 7 days, the supernatant was collected and purified with protein A to obtain purified hybridoma monoclonal antibody.

[0181] The hybridoma antibodies from the above-mentioned isolates were identified by ELISA, FACS, etc., and two mouse candidate antibodies, mAb-1 and mAb-2, with good binding activity were obtained.

[0182] Example 3: Construction and preparation of anti-LRRC15 chimeric antibody

[0183] Using molecular biology techniques, DNA sequences encoding heavy and light chain immunoglobulins were obtained from the aforementioned hybridoma mouse antibodies, and chimeric antibodies were constructed after sequencing.

[0184] Following Homo sapiens' codon usage preferences, the coding nucleic acids for the amino acid sequences of the hybridoma antibody heavy chain variable region (VH) and light chain variable region (VL) were codon-optimized, followed by full-sequence synthesis. The heavy chain variable region was cloned into a PTT5 vector containing the human heavy chain constant region (Table 1, SEQ ID NO:5) and regulatory elements to express the complete IgG heavy chain in mammalian cells. Similarly, the light chain variable region was cloned into a PTT5 vector containing the human light chain constant region (Table 1, SEQ ID NO:7) and regulatory elements to express the complete IgG light chain in mammalian cells. After correct sequencing, the proteins were transfected into Expi-293 mammalian cells. The proteins were expressed and secreted into the culture medium, and the supernatants were collected, filtered, and purified. Protein A chromatography was used to purify the proteins. The culture supernatant was loaded onto a suitably sized Protein A column and washed with 3–5 column volumes of high-salt eluent (20 mM phosphate buffer, 1 M NaCl, pH 7.4). Elute with elution buffer (50 mM NaAc-HAc, pH 3.5). Concentrate the protein by ultrafiltration using a Millipore tube and measure the OD. 280nm The protein concentration was determined by spectrophotometry. SDS-PAGE analysis was used to analyze the aggregation or degradation of the purified protein, yielding chimeric antibodies CHI-1 and CHI-2 with VH and VL sequences identical to those of the murine antibodies mAb-1 and mAb-2. The murine / chimeric antibodies VH and VL and their CDR sequences are shown in Tables 3 and 4 below.

[0185] Table 3: Murine / Chimeric Antibody VH and VL Sequences

[0186] Table 4: CDRs of murine / chimeric antibody molecules

[0187] Example 4 Identification of LRRC15 chimeric antibody

[0188] 4.1 Enzyme-linked immunosorbent assay (ELISA) to detect the binding of chimeric antibodies to human / mouse LRRC15 protein.

[0189] Dilute goat anti-human IgG with PBS pH 7.4 (Meilune, CAT#PWL050) Add Fc antibody (Jackson, CAT:109-006-098) to a concentration of 4 μg / mL to an ELISA plate (corning, CAT#9018), 50 μL / well, and incubate overnight at 4°C. Discard the coating solution, add 5% skim milk powder (Sangon Biotech, CAT#A600669-0250)-PBS, 250 μL / well, and incubate at 37°C for 2–4 hours. Wash three times with 0.05% Tween 20-PBS (Sangon Biotech, CAT#A100777-0500, B548117-0500) using a plate washer (Biotek, CAT#405TUS). Dilute human LRRC15-mFc (prepared in Example 1.2) with 1% BSA to a concentration of 200 ng / mL, add to an ELISA plate, 50 μL / well, and incubate at 37°C for 2 hours. After washing three times with 0.05% Tween 20-PBS, add chimeric antibodies CHI-1 and CHI-2 (1% BSA diluted to 15 nM, serially diluted 6-fold to 8 concentration points), 50 μL / well, and incubate at 37°C for 1.5–2 hours. Wash three times with 0.05% Tween 20-PBS. Dilute HRP enzyme-labeled antibody (Merck, CAT#AP113P) with 1% BSA (Sangon Biotech, CAT#A500023-0100)-PBS at a 1:5000 ratio, add 50 μL / well, and incubate at 37°C for 1 hour. Wash three times with 0.05% Tween 20-PBS. Add TMB chromogenic solution (Seracare, CAT#5120-0077), 50 μL / well, and incubate at room temperature for 5–10 minutes. Add 1M... HCl, 50 μL / well, to terminate the reaction, read OD using a microplate reader (Biotek, Powerwave HT). 450nm .

[0190] The detection results of the chimeric antibody and protein are shown in Table 5, indicating that the chimeric antibody can bind to the human / mouse LRRC15 protein. The isotype control antibody was an anti-FITC antibody (prepared in Example 1.1), and the data in the table represent OD values. 450nm value.

[0191] Table 5: ELISA detection of the binding reaction between chimeric antibodies and human / mouse LRRC15 protein Note: " / " indicates no combination.

[0192] 4.2 Flow cytometry (FACS) assay to detect the binding activity of chimeric antibodies to endogenous cells

[0193] Saos-2 cells (human osteosarcoma cells, purchased from Nanjing Kebai, catalog number: CBP60742) highly expressing human LRRC15 protein, U118-MG cells (human astroblastoma cells, purchased from Nanjing Kebai, catalog number: CBP60305) highly expressing human LRRC15 protein, and LLC cells (mouse lung cancer cells, purchased from Shanghai Institute of Cell Bank, Chinese Academy of Sciences, catalog number: TCM7) moderately expressing mouse LRRC15 protein were cultured in T-75 cells. Expand the cells to the logarithmic growth phase in cell culture flasks, centrifuge and discard the supernatant. Wash the cell pellet once with PBS and seed them into 96-well plates at a density of 2E5 cells / well. Centrifuge at 1500 rpm for 5 minutes and discard the supernatant. Dilute the chimeric antibodies CHI-1 and CHI-2 to 50 nM, perform a 4-fold serial dilution for 8 spots, add 100 μL to each well, resuspend the cells, incubate at 4°C for 1 hour, wash twice with PBS, and add 100 μL of secondary antibody (Alexa) to each well. 647 Affini Pure Goat Anti-Human IgG (H+L), Jackson Immuno, 109-605-088), incubated at 4°C for 1 hour, washed twice with PBS, and then detected and analyzed by FACS (FACS Canto II, purchased from BD). The results are shown in Table 6. The chimeric antibodies CHI-1 and CHI-2 could both specifically bind to the above-mentioned endogenous cells Saos-2, U118-MG, and LLC cells.

[0194] Table 6: FACS detection of the binding activity of chimeric antibodies to endogenous cells Saos-2, U118-MG and LLC Note: " / " indicates no combination.

[0195] Example 5: Screening of nanobodies targeting the LRRC15 protein

[0196] 5.1 Animal immunization and serum titer detection

[0197] Two camels approximately 3 years old were selected. 5 ml of blood was collected before immunization and used as a negative control serum. For the initial immunization, 0.5 mg of human LRRC15-hFC protein prepared in Example 1.2 was thoroughly mixed with Freund's complete adjuvant (purchased from Sigma, F5881) and injected subcutaneously at multiple sites in the neck. Two weeks later, a second immunization was performed, with 0.25 mg of mouse LRRC15-hFC protein prepared in Example 1.2 mixed with Freund's incomplete adjuvant and injected subcutaneously at multiple sites in the neck. Serum titers were measured one week later. Camel #1 was immunized five times with human and mouse LRRC15 protein alternately, while camel #2 was immunized six times. Enzyme-linked immunosorbent assay (ELISA) was used to detect the antibody titers and specificities against human and mouse LRRC15 proteins in the serum. The results showed that the immunized camel serum effectively bound to the immunogens, exhibiting an antigen-antibody reaction.

[0198] 5.2 Construction of Nanoparticle Antibody Phage Library

[0199] 200 mL of peripheral blood was collected from camel #1 after its fifth immunization, and 200 mL of peripheral blood was collected from camel #2 after its fifth and sixth immunizations. Peripheral blood cells (PBMCs) were isolated using lymphocyte separation medium. Total RNA was extracted post-immunization using Trizol reagent and processed according to the PrimeScript reverse transcription kit. TM II. cDNA was obtained using the 1st Strand cDNA Synthesis Kit (Takara, 6210A). Nested PCR was used to amplify the nanobody (VHH) fragment. The first amplification yielded different IgG isoforms, and the gene fragments of IgG2 and IgG3 (600-800 bp) were recovered from the gel. The second amplification yielded the VHH-specific fragment, simultaneously inserting an SfiI restriction enzyme site. The target band size after the second round of amplification was approximately 500 bp. After purification, the PCR product was ligated into the phage display vector pComb3Xss using the restriction endonuclease SfiI (purchased from NEB, R0123L), and the ligation product was purified. The ligation product was then electroporated into TG1 competent cells (LUCIGEN, 60502-2) for a total of 10 electroporations. Immediately after each electroporation, 1 mL of SOC medium (LUCIGEN, 60502-2, provided with the TG1 competent cells) was added to the electroporation vessel for 1 hour of recovery culture, yielding a total of 10.5 mL of TG1 cell recovery product. TG1 bacterial culture serially diluted 10 3 Double 10 4 The number of transformants in the nanobody library was determined by multiplying the number of transformants by 10. 3 and 10 4 The diluted TG1 bacterial suspension was spread onto 150 mm plates, and the remaining bacterial suspension was spread onto three 500 cm² plates. 2 On the flat surface. The calculated storage capacity is 2.86 × 10⁵ for Camel No. 1 (free of charge).9 Camel No. 2, free storage capacity 1.45×10 9 The No. 2 Camel No. 6 Free Storage Capacity is 1.52 × 10 9 Sequencing of 96 samples showed an insertion rate of approximately 99% and sequence diversity of over 96%, indicating successful library construction.

[0200] 5.3 Screening of LRRC15 nanobodies

[0201] The LRRC15 nanobody disclosed herein was obtained by cross-panning of human and mouse LRRC15 proteins. For the first round of biopanning, multiple 2ml low-adsorption EP tubes (purchased from Eppendorf) were prepared. 100μL of streptavidin-conjugated Dynabeads (purchased from Invitrogen) was added to each low-adsorption EP tube, followed by blocking buffer (PBS phosphate buffer containing 5% (w / v) BSA). The tubes were blocked at room temperature for 2 hours, then placed on a magnetic rack for 30 seconds. The liquid inside the tube was removed, and the tubes were washed three times with PBS. 1ml of the above-mentioned phage library was added to the blocked Dynabeads, and 1 / 5 volume of 5% (w / v) BSA / PBS was added. The tube was placed on a four-dimensional spin mixer and incubated at room temperature for 1 hour. After 1 hour, the tube was placed on a magnetic rack, and the phage supernatant was collected. Place the phage supernatant into a new 1.5 ml EP tube, add 2 μg of biotinylated human LRRC15-His protein (prepared in Example 1.2), and perform biotinylation according to the kit instructions (purchased from Tongren Chemical, LK03). Place the tube on a four-dimensional spin mixer and incubate at room temperature for 1 hour. After 1 hour, add the incubated phage and antigen complex to pre-blocked Dynabeads, place the tube on a four-dimensional spin mixer, and incubate at room temperature for 20 minutes. Then, place the tube on a magnetic rack, remove the supernatant, and begin washing: wash repeatedly with 0.05% PBST, aspirating the solution and adding fresh washing buffer, for a total of 10 washes; finally, wash with PBS, agitating the solution repeatedly, aspirating the solution and adding fresh washing buffer, for a total of 2 washes; after washing, place the tube on a magnetic rack to remove the supernatant. Add 500 μl of 10 μg / mL trypsin to each tube and incubate at 37°C for 15 minutes to elute phages bound to biotinylated human LRRC15-His protein. Add 450 μl of trypsin solution to 10 mL of E. coli TG1 (purchased from LUCIGEN) in logarithmic growth phase and incubate at 37°C for 45 minutes to obtain TG1 culture medium. Serially dilute the TG1 culture medium, plate it, and incubate overnight at 37°C. Calculate the number of clones bound to biotinylated human LRRC15-His protein and select 48 clones for sequencing. Simultaneously, wash and collect the clones on the plates with 2YT medium (Sangon Biotech, A507019) and inoculate them into fresh medium, incubating at 37°C to logarithmic growth phase. Add helper phage M13KO7 (purchased from NEB, catalog number N0315S) at a ratio of 20:1 to E. coli TG1, mix well, and incubate at 37°C for 45 minutes. Then, centrifuge at 4000 rpm for 10 minutes to collect the cells, add fresh 2YT medium containing ampicillin and kanamycin resistance, and incubate overnight at 30°C with shaking. Centrifuge at 5000 rpm for 20 minutes, collect the supernatant, add 1 / 4 volume of the supernatant to a 2.5M NaCl solution containing 20% ​​PEG6000, and incubate on ice for 2 hours.Centrifuge at 5000 rpm and 4°C for 30 minutes to collect the phage pellet, and dissolve it in PBS buffer. Centrifuge at 10000 rpm for 10 minutes to remove residual cell debris, and collect the supernatant for the next round of biopanning.

[0202] The second round of screening followed the same steps as the first, enriching VHH antibodies that specifically bind to biotinylated mouse LRRC15-His protein. Through multiple rounds of screening, positive phages were continuously enriched during the process to identify nanobodies with high specificity and affinity.

[0203] 5.4 Screening for positive phage clones using enzyme-linked immunosorbent assay (ELISA)

[0204] Single clones were selected from panning plates and cultured in 96-well plates with 2 YT medium added to each well. The plates were incubated overnight at 37°C with shaking at 250 rpm. The next day, the overnight culture was cultured until the OD600 reached 0.4-0.6. Helper phages were added at a ratio of 20:1 for infection, followed by another 2 YT medium and incubation overnight. On the third day, the supernatant obtained after centrifugation was added to a blocked ELISA plate indirectly coated with human and mouse LRRC15 protein (prepared in Example 1.2). Horseradish peroxidase-labeled anti-M13 antibody (purchased from Sinocare, 11973-MM05T-H) was added for incubation. After washing, TMB chromogenic buffer (purchased from KPL, 52-00-02) was added for color development, and the results were measured at 450 nm using a microplate reader. Positive clones simultaneously binding to human and mouse LRRC15 protein were selected for FACS detection.

[0205] 5.5 Flow cytometry screening for positive phage clones

[0206] Endogenous tumor cell lines U-87MG (from CAS-TCHu138) and LLC (from Shanghai CAS-TCM7) were cultured in T-175 cell culture flasks to 90% confluence. The culture medium was aspirated, and the cells were washed once with PBS buffer, then treated with Trypsin-EDTA (Gibco, catalog number 25200072) and collected. After cell counting, the cells were washed twice with PBS phosphate buffer and diluted to 2 × 10⁻⁶. 6Cells were added at a rate of 50 μL per well to a 96-well FACS plate. FACS buffer was prepared by adding 1% (w / w) fetal bovine serum to PBS phosphate buffer and washing twice by centrifugation at 1000 rpm and 4°C. 50 μL of phage supernatant was added to each well, and the plate was incubated on ice for 1 hour. Cells were washed three times by centrifugation with FACS buffer. 50 μL of 1:1000 diluted anti-M13 antibody (Sinochem, catalog number 11973-MM05T) was added to each well, and the plate was incubated on ice for 1 hour. Cells were washed three times by centrifugation with FACS buffer. Alexa 647-labeled secondary antibody (Jackson Immuno, catalog number 115-605-003) was added to each well, and the plate was incubated on ice for 1 hour. Cells were washed three times by centrifugation with FACS buffer. Cells were resuspended in 100 μL of FACS buffer, and the results were analyzed using FACS. According to the method in Example 4.1, the supernatant of positive clone phages that cross-binded with both human and mouse LRRC15 protein and cells was added to a blocked ELISA plate indirectly coated with monkey LRRC15 protein (prepared in Example 1.2). Horseradish peroxidase-labeled anti-M13 antibody (purchased from Sinocare, 11973-MM05T-H) was added for incubation. After washing, TMB chromogenic solution (purchased from KPL, 52-00-02) was added for color development. The color development results were measured using an ELISA reader at A405nm.

[0207] According to the method in Example 4.2, positive clones that cross-bind with human, mouse, and monkey LRRC15 proteins and cross-bind with human and mouse cells were detected using FlpinCHO-cyno LRRC15 and corresponding control cell lines.

[0208] After multiple rounds of optimization and screening, one positive clone capable of simultaneously recognizing the LRRC15 protein in humans, mice, and monkeys was obtained and named Lab-3. Its sequence CDRs were analyzed using KABAT, Chothia, or IMGT software, and the corresponding sequence information is shown in Tables 7 and 8 below. Table 7 shows the amino acid sequence of the variable region of the camel nanobody molecule, and Table 8 shows the KABAT, IMGT, and Chothia analysis results of the camel nanobody molecule's CDRs.

[0209] Table 7: Amino acid sequence information of the variable region of the anti-LRRC15 nanobody

[0210] Table 8: Specific sequence information of CDRs of LRRC15 nanobody analyzed by Kabat, IMGT and Chothia software

[0211] 5.6 Expression, purification, and affinity detection of recombinant nanobodies

[0212] 5.6.1 Protein A affinity chromatography purification of recombinant nanobodies

[0213] The variable region sequence of the nanobody Lab-3 obtained in Example 5.5 was cloned into the eukaryotic expression vector pTT5 (Ubibio, VT2202) with an Fc tag (SEQ ID NO: 10 in Table 2). HEK293 cells (purchased from Gibco, A14527) were transiently transfected with PEI (Polysciences, 24765-1) and cultured for 6 days. The cell culture supernatant expressing the antibody was collected by high-speed centrifugation. After protein A affinity purification, the Fc-tagged antibody eluted from the chromatography column was collected to obtain the recombinant nanobody, named CHI-3.

[0214] 5.6.2 Enzyme-linked immunosorbent assay (ELISA) to detect the binding of recombinant antibodies to human, mouse, and monkey LRRC15-his proteins.

[0215] Anti-his tag antibody and mouse monoclonal protein (purchased from Sino) were diluted to a final concentration of 1 μg / mL with PBS, and then 50 μl was added to each well of a 96-well ELISA plate and incubated overnight at 4°C. The next day, the plates were washed twice with PBST, and blocking buffer [PBS + 2% (w / w) BSA] was added and blocked at room temperature for 2 hours. The blocking buffer was discarded, and human, mouse, and monkey LRRC15-his protein (prepared in Example 1.2) were diluted to a final concentration of 0.2 μg / mL with PBS, and then 50 μl was added to each well of a 96-well ELISA plate and incubated at room temperature for 1 hour. Recombinant antibody (starting at 25 nM, serially diluted 6-fold), positive and negative control antibodies (50 μl per well) were added. After incubation at 37°C for 1 hour, the plates were washed three times with PBST. HRP (horseradish peroxidase)-labeled secondary antibody (purchased from Merck, catalog number: AP113P) was added, and after incubation at 37°C for 1 hour, the plates were washed five times with PBST. Add 50 μl of TMB substrate to each well and incubate at room temperature for 10 minutes. Then add 50 μl of stop solution (1.0 M HCl) to each well. Use an ELISA plate reader (Multimode Plate Reader, EnSight, Perkin Elmer) to read the OD value at 450 nm. The purified recombinant antibody CHI-3 effectively bound to human, mouse, and monkey LRRC15-his protein (Table 9).

[0216] Table 9: ELISA detection of the binding activity of chimeric antibody CHI-3 to human / mouse / monkey LRRC15 protein Note: " / " indicates no combination.

[0217] 5.6.3 Flow cytometry (FACS) assay to detect the binding of recombinant antibodies to human, mouse, and monkey LRRC15.

[0218] Endogenous tumor cells U-87MG (highly expressing human LRRC15), LLC (medium expressing mouse LRRC15), and FlpinCHO-cyno LRRC15, along with corresponding control cell lines, were cultured in T-175 culture flasks to the logarithmic growth phase. The affinity of CHI-3 for cell binding was tested according to the method described in Example 4.2. Analysis showed that the recombinant antibody CHI-3 specifically bound to U-87MG, LLC, and FlpinCHO-cyno LRRC15 cells (Table 10).

[0219] Table 10: FACS detection of binding activity of chimeric antibody CHI-3 to endogenous cells Note: " / " indicates no combination.

[0220] Example 6 Humanization of Antibodies

[0221] By comparing with the IMGT (http: / / imgt.cines.fr) human antibody heavy and light chain variable region germline gene database, heavy and light chain variable region germline genes with high homology to murine antibodies were selected as templates. The CDRs of the murine antibodies were transplanted into the corresponding human templates, forming variable region sequences in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Based on the three-dimensional structure of the antibody, reverse mutations were performed on embedded residues, residues that directly interact with the CDR region, and residues in the framework regions that have an important influence on the conformation of VL and VH, thus obtaining humanized monoclonal antibodies. The CDR amino acid residues of the antibody were determined and annotated using the Kabat numbering system.

[0222] Humanization of 6.1 mAb-1

[0223] The heavy chain of the murine antibody mAb-1 was first mutated N73D to remove glycosylation sites, and the resulting heavy chain sequence was named huAb-1.VHA. Humanized light chain templates were IGKV1-17*01 and IGKJ4*01, and humanized heavy chain templates were IGHV1-3*01 and IGHJ6*01. The CDR of the murine antibody mAb-1 was transplanted into its corresponding human templates to obtain the corresponding humanized versions of huAb-1. As needed, key amino acids in the FR region sequence of the humanized mAb-1 were reverse-mutated to the corresponding amino acids of the murine antibody to maintain the original affinity (antibodies have sites prone to chemical modification; point mutations at these sites are performed to eliminate the risk of modification). Specific reverse-mutation designs are shown in Table 11.

[0224] Table 11: Humanized Antibody Reverse Mutation Design for huAb-1 Note: Graft indicates that the murine antibody CDR was inserted into the FR region sequence of the human template; V68A indicates that the V at position 68 of Graft was mutated to A, and so on. The amino acid sequence numbering of the reverted mutant is in natural order.

[0225] Table 12: Humanized antibody mutation design for huAb-1 (kabat encoding)

[0226] Table 13: Humanized antibody mutation design for huAb-1 (IMGT encoding)

[0227] The specific sequence of the variable region of the huAb-1 humanized antibody is as follows:

[0228] The amino acid sequence of huAb-1.VL3 is shown in SEQ ID NO:52:

[0229] The amino acid sequence of huAb-1.VH3 is shown in SEQ ID NO:53:

[0230] The amino acid sequence of huAb-1.VH3b is shown in SEQ ID NO:54:

[0231] The amino acid sequence of huAb-1.VH4b is shown in SEQ ID NO:55:

[0232] The amino acid sequence of the humanized light chain template IGKV1-17*01 is shown in SEQ ID NO:56:

[0233] The amino acid sequence of the humanized light chain template IGKJ4*01 is shown in SEQ ID NO:57:

[0234] The amino acid sequence of the humanized heavy chain template IGHV1-3*01 is shown in SEQ ID NO:58:

[0235] The amino acid sequence of the humanized heavy chain template IGHJ6*01 is shown in SEQ ID NO:59:

[0236] This disclosure involves selecting different light and heavy chain sequences for cross-combination from the reversion mutation design of the variable regions of the light and heavy chains of the humanized antibodies of huAb-1 mentioned above, and finally obtaining a variety of humanized antibodies of huAb-1 (Table 14).

[0237] Table 14: Variable regions of light and heavy chains of huAb-1 humanized antibody

[0238] According to the Kabat numbering system, the CDRs analysis results of the above-mentioned humanized antibody VH and VL sequences are shown in Table 15.

[0239] Table 15: Kabat analysis results of VH and VL sequences of huAb-1 humanized antibody

[0240] Humanization of 6.2 mAb-2

[0241] The light chain of the murine antibody mAb-2 was first mutated at S32P to remove glycosylation sites, and the resulting light chain sequence was named huAb-2.VLA. Humanized light chain templates were IGKV4-1*01 and IGKJ2*01, and humanized heavy chain templates were IGHV1-46*01 and IGHJ6*01. The CDR of the murine antibody mAb-2 was transplanted into its corresponding human templates to obtain the corresponding humanized versions of huAb-2. As needed, key amino acids in the FR region sequence of the humanized huAb-2 antibody were reverse-mutated to the corresponding amino acids of the murine antibody to maintain the original affinity (antibodies have sites prone to chemical modification; point mutations at these sites are performed to eliminate the risk of modification). Specific reverse-mutation designs are shown in Table 16.

[0242] Table 16: Humanized Antibody Reverse Mutation Design for huAb-2 Note: Graft indicates that the murine antibody CDR was inserted into the FR region sequence of the human template; R72V indicates that the R at position 72 of Graft was mutated to V, and so on. The reverted mutated amino acids are numbered in natural sequence.

[0243] Table 17: Humanized antibody mutation design for huAb-2 (Kabat encoding)

[0244] Table 18: Humanized antibody mutation design for huAb-2 (IMGT encoding)

[0245] The specific sequence of the variable region of the huAb-2 humanized antibody is as follows:

[0246] The amino acid sequence of huAb-2.VL3 is shown in SEQ ID NO:61:

[0247] The amino acid sequence of huAb-2.VH1 is shown in SEQ ID NO:62:

[0248] The amino acid sequence of huAb-2.VH2 is shown in SEQ ID NO:63:

[0249] The amino acid sequence of huAb-2.VH3 is shown in SEQ ID NO:64:

[0250] The amino acid sequence of the humanized light chain template IGKV4-1*01 is shown in SEQ ID NO:65:

[0251] The amino acid sequence of the humanized light chain template IGKJ2*01 is shown in SEQ ID NO:66:

[0252] The amino acid sequence of the humanized heavy chain template IGHV1-46*01 is shown in SEQ ID NO:67:

[0253] The amino acid sequence of the humanized heavy chain template IGHJ6*01 is shown in SEQ ID NO:68:

[0254] This disclosure involves selecting different light and heavy chain sequences for cross-combination from the reversion mutation design of the variable regions of the light and heavy chains of the humanized antibodies against huAb-2, respectively, to finally obtain a variety of humanized antibodies against huAb-2 (Table 19).

[0255] Table 19: Variable regions of light and heavy chains of huAb-2 humanized antibody

[0256] According to the Kabat numbering system, the CDRs analysis results of the above-mentioned humanized antibody VH and VL sequences are shown in Table 20.

[0257] Table 20: Kabat analysis results of VH and VL sequences of huAb-2 humanized antibody

[0258] 6.3 Humanization of Lab-3

[0259] The VHH single-domain antibody Lab-3 obtained by camel phage display has humanized heavy chain templates of IGHV3-21*01 or IGHV3-7*01 and IGHJ6*01 or IGHJ3*01. The CDR of VHH single-domain antibody Lab-3 is transplanted into its humanized template to obtain the corresponding humanized version huAb-3. As needed, key amino acids in the FR region sequence of the humanized huAb-3 antibody are reverse-mutated to the corresponding amino acids of the VHH single-domain antibody to maintain the original affinity (antibodies have sites prone to chemical modification; point mutations are performed on these sites to eliminate the risk of modification). Specific reverse mutation designs are shown in Table 21.

[0260] Table 21: Humanized Antibody Reverse Mutation Design for huAb-3 Note: Graft represents the insertion of the VHH single-domain antibody CDR into the FR region sequence of the human template; A97G indicates that the A at position 97 of Graft is mutated to G, and so on. The reverted mutated amino acids are numbered in natural sequence.

[0261] Table 22: Humanized antibody mutation design for huAb-3 (Kabat encoding)

[0262] Table 23: Humanized antibody mutation design for HuAb-3 (IMGT encoding)

[0263] The specific sequence of the variable region of the HuAb-3 humanized antibody is as follows:

[0264] The amino acid sequence of HuAb-3-H1 is shown in SEQ ID NO:69:

[0265] The amino acid sequence of HuAb-3-H2 is shown in SEQ ID NO:70:

[0266] The amino acid sequence of HuAb-3-H7 is shown in SEQ ID NO: 71:

[0267] The amino acid sequence of the humanized heavy chain template IGHV3-7*01 is shown in SEQ ID NO:72:

[0268] The amino acid sequence of the humanized heavy chain template IGHJ3*01 is shown in SEQ ID NO:73:

[0269] The amino acid sequence of the humanized heavy chain template IGHV3-21*01 is shown in SEQ ID NO:74:

[0270] According to the Kabat numbering system, the results of the VHH sequence analysis of the above-mentioned humanized single-domain antibody are shown in Table 24.

[0271] Table 24: Kabat analysis results of the VHH sequence of the humanized single-domain antibody HuAb-3

[0272] 6.4 Humanization of M25

[0273] The humanized light chain templates for the murine antibody M25 against LRRC15 (the variable region sequence of the antibody is derived from US7399469B2 (see Table 25 below), and the heavy / light chain constant regions are SEQ ID NO: 5 and 7 in Table 1, respectively) are IGKV3-11*01 and IGKJ4*01, and the humanized heavy chain templates are IGHV7-4-1*04 and IGHJ1*01. The CDRs of the murine antibody M25 were transplanted into their respective humanized templates to obtain the corresponding humanized version, huAb-4. As needed, key amino acids in the FR region sequence of the humanized M25 antibody were reverse-mutated to the corresponding amino acids of the murine antibody to maintain the original affinity (antibodies have sites prone to chemical modification; point mutations at these sites are performed to eliminate the risk of modification and simultaneously increase the immunogenicity of the molecule). Specific reverse-mutation designs are shown in Table 25.

[0274] Table 25: Sequence information of anti-human LRRC15 antibody M25 Note: The underlined part is the signal peptide.

[0275] Table 26: Humanized Antibody Reverse Mutation Design for HuAb-4 Note: Graft indicates that the murine antibody CDR was inserted into the FR region sequence of the human template; T28K indicates that the T at position 28 of Graft was mutated to K, and so on. The amino acid sequence numbering of the reverted mutated amino acid is in natural order.

[0276] Table 27: Humanized antibody mutation design for HuAb-4 (Kabat encoding)

[0277] Table 28: Humanized antibody mutation design for huAb-4 (IMGT encoding)

[0278] The specific sequence of the variable region of the huAb-4 humanized antibody is as follows:

[0279] The amino acid sequence of huAb-4.VL4 is shown in SEQ ID NO:77:

[0280] The amino acid sequence of huAb-4.VH1 is shown in SEQ ID NO:78:

[0281] The amino acid sequence of huAb-4.VH3 is shown in SEQ ID NO:79:

[0282] The amino acid sequence of huAb-4.H1F is shown in SEQ ID NO:80:

[0283] The amino acid sequence of the humanized light chain template IGKV3-11*01 is shown in SEQ ID NO:81:

[0284] The amino acid sequence of the humanized heavy chain template IGHV7-4-1*04 is shown in SEQ ID NO:82:

[0285] The amino acid sequence of the humanized heavy chain template IGHJ1*01 is shown in SEQ ID NO:83:

[0286] This disclosure selects different light and heavy chain sequences for cross-combination from the reverse mutation design of the light and heavy chain variable regions of the humanized antibodies of huAb-4 mentioned above, and finally obtains a variety of humanized antibodies of huAb-4. The light and heavy chain variable regions of each antibody are shown in Table 29.

[0287] Table 29: Variable regions of light and heavy chains of huAb-4 humanized antibody

[0288] According to the Kabat numbering system, the sequence analysis results of the above-mentioned humanized antibodies VH and VL are shown in Table 30.

[0289] Table 30: Kabat analysis results of VH and VL sequences of huAb-4 humanized antibody

[0290] 6.5 Enzyme-linked immunosorbent assay (ELISA) to detect the binding of humanized antibodies to human, cynomolgus monkey and mouse LRRC15 proteins.

[0291] Using human, cynomolgus monkey, and mouse LRRC15-mFc (prepared in Example 1.2) as antigens, the binding affinity of the humanized antibodies of this disclosure to the LRRC15 protein was detected by ELISA and the data were analyzed according to the method described in Example 4.1. As shown in Table 31, all the humanized antibodies of this disclosure can effectively bind to human, cynomolgus monkey, and mouse LRRC15-mFc.

[0292] Table 31: ELISA detection of the binding reaction between humanized antibodies and human / cynomolgus monkey / mouse LRRC15 protein

[0293] 6.6 Flow cytometry (FACS) assay to detect the binding activity of humanized antibody to U-118MG

[0294] U118-MG cells (human astroblastoma, purchased from Nanjing Kebai, catalog number: CBP60305) with high expression of human LRRC15 protein were cultured in T-75 cell culture flasks to the logarithmic growth phase. Following the method described in Example 4.2, the binding affinity of the humanized antibody of this disclosure to U-118MG was detected by FACS and the data were analyzed. As shown in Figure 1 and Table 32, all the humanized antibodies prepared in this disclosure can effectively bind to U-118MG cells.

[0295] 6.7 Flow cytometry (FACS) assay to detect the binding activity of humanized antibody to 293T-huLRRC15

[0296] 293T-huLRRC15 (the 293T-huLRRC15 constructed in Example 1.3.2) was cultured in T-75 cell culture flasks to the logarithmic growth phase. Following the method described in Example 4.2, the binding affinity between the humanized antibody of this disclosure and 293T-huLRRC15 was detected by FACS and analyzed. As shown in Figure 2 and Table 32, all humanized antibodies prepared in this disclosure can effectively bind to 293T-huLRRC15 cells (in this analysis, all data came from the same batch of experiments using the same positive control; to more clearly compare the effects of different chimeras and corresponding humanized sequences, positive control data were placed for each group in the charts).

[0297] Table 32: FACS detection of binding activity of humanized antibodies with U118-MG and 293T-hLRRC15

[0298] All teachings of the patents, publications, and references cited herein are incorporated herein by reference in their entirety. While exemplary embodiments have been specifically shown and described, those skilled in the art will understand that various changes in form and detail may be made therein without departing from the scope of the embodiments covered by the appended claims.

Claims

1. An antibody or antigen binding fragment that specifically binds to LRRC15, characterized in that, The antibody or antigen-binding fragment comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein the VH comprises HCDR1-3 and the VL comprises LCDR1-3. The HCDR1-3 has the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH as shown in any one of SEQ ID NO:13-14, 53-55, 62-64, and 80; and / or; The LCDR1-3 have the amino acid sequences of LCDR1, LCDR2 and LCDR3 as shown in any one of SEQ ID NO:15-16, 52, 61 and 77.

2. The antibody or antigen-binding fragment of claim 1, wherein, The antibody or antigen-binding fragment comprises: (1) The amino acid sequences of HCDR1-3 of VH shown in any one of SEQ ID NO:13 and 53-55, and the amino acid sequences of LCDR1-3 of VL shown in SEQ ID NO:15 or 52; or, (2) The amino acid sequences of HCDR1-3 of VH shown in any one of SEQ ID NO:14 and 62-64, and the amino acid sequences of LCDR1-3 of VL shown in SEQ ID NO:16 or 61; or, (3) The amino acid sequences of HCDR1-3 of VH shown in any one of SEQ ID NO:78-80, and the amino acid sequences of LCDR1-3 of VL shown in SEQ ID NO:77; Preferably, the antibody or antigen-binding fragment comprises: (1) The amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:13, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:

15. (2) The amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:14, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:

16. (3) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH as shown in any one of SEQ ID NO:53-55, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO:52; or (4) The amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH as shown in any one of SEQ ID NO:62-64, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:61; preferably, the HCDR1-3 and / or the LCDR1-3 are determined according to the Kabat, IMGT or Chothia method.

3. The antibody or antigen-binding fragment according to claim 1 or 2, characterized in that, The HCDR1-3 has an amino acid sequence selected from the following group: (1) The amino acid sequences shown in SEQ ID NO:17-19; SEQ ID NO:29-31; SEQ ID NO:39-40 and 19; or SEQ ID NO:17-18 and 60; (2) The amino acid sequences shown in SEQ ID NO:23-25; SEQ ID NO:34-36; or SEQ ID NO:41-42 and 25; (3) The amino acid sequences shown in SEQ ID NO: 87 and 85-86; and / or The LCDR1-3 has an amino acid sequence selected from the group consisting of: (1) The amino acid sequences shown in SEQ ID NO:20-22; or SEQ ID NO:32-33 and 22; (2) The amino acid sequences shown in SEQ ID NO:26-28; or SEQ ID NO:37-38 and 28; (3) The amino acid sequence shown in SEQ ID NO:88-90.

4. The antibody or antigen binding fragment of any one of claims 1-3, wherein, The HCDR1-3 and the LCDR1-3 each have a sequence selected from the following group: (1) The HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:17-19, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:20-22; or the HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:29-31, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:32-33 and 22; or the HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:39-40 and 19, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:20-22; or the HCDR1-HCDR3 respectively have the amino acid sequences shown in SEQ ID NO:17-18 and 60, and the LCDR1-LCDR3 respectively have the amino acid sequences shown in SEQ ID NO:20-22; or (2) The HCDR1-HCDR3 each have the amino acid sequences shown in SEQ ID NO:23-25, and the LCDR1-LCDR3 each have the amino acid sequences shown in SEQ ID NO:26-28; or the HCDR1-HCDR3 each have the amino acid sequences shown in SEQ ID NO:34-36, and the LCDR1-LCDR3 each have the amino acid sequences shown in SEQ ID NO:37-38 and 28; or the HCDR1-HCDR3 each have the amino acid sequences shown in SEQ ID NO:41-42 and 25, and the LCDR1-LCDR3 each have the amino acid sequences shown in SEQ ID NO:26-28; or (3) The HCDR1-HCDR3 have the amino acid sequences shown in SEQ ID NO:87 and 85-86 respectively, and the LCDR1-LCDR3 have the amino acid sequences shown in SEQ ID NO:88-90 respectively.

5. The antibody or antigen binding fragment of any one of claims 1-4, wherein, The heavy chain variable region VH comprises an amino acid sequence as shown in any one of SEQ ID NO: 13-14, 53-55, 62-64, and 78-80, or an amino acid sequence having at least 70% identity or up to 15 mutations compared to it; and / or, The light chain variable region VL contains an amino acid sequence as shown in any one of SEQ ID NO:15-16, 52, 61 and 77, or an amino acid sequence having at least 70% identity or up to 15 mutations compared to it. Preferably, the antibody or antigen-binding fragment comprises: (1) VH as shown in SEQ ID NO:13, and VL as shown in SEQ ID NO:15; (2) VH as shown in SEQ ID NO:14, and VL as shown in SEQ ID NO:16; (3) VH as shown in any one of SEQ ID NO:53-55, and VL as shown in SEQ ID NO:52; (4) VH as shown in any one of SEQ ID NO:62-64 and VL as shown in SEQ ID NO:61; or (5) VH as shown in any one of SEQ ID NO:78-80 and VL as shown in SEQ ID NO:

77.

6. An antibody or antigen binding fragment that specifically binds to LRRC15, characterized in that, The antibody or antigen-binding fragment includes a heavy chain variable region VH, the VH containing HCDR1-3, the HCDR1-3 having the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the VH as shown in any one of SEQ ID NO:43 and 69-71.

7. The antibody or antigen-binding fragment of claim 6, wherein, The HCDR1-3 has an amino acid sequence selected from the group consisting of: SEQ ID NO:44-46; SEQ ID NO:47-49; or SEQ ID NO:50-51 and 46; Preferably, the HCDR1-3 and / or the LCDR1-3 are determined according to the Kabat, IMGT, or Chothia method.

8. The antibody or antigen binding fragment of claim 6 or 7, wherein, The heavy chain variable region VH contains an amino acid sequence as shown in any one of SEQ ID NO:43 and 69-71, or an amino acid sequence having at least 70% identity or up to 15 mutations compared to it.

9. The antibody or antigen binding fragment of any one of claims 1-8, wherein, The antibody or antigen-binding fragment further comprises a heavy chain constant region CH and / or a light chain constant region CL; preferably, the heavy chain constant region is selected from human or mouse IgG1, IgG2, IgG3 or IgG4 constant regions; and / or the light chain constant region is selected from human or mouse kappa constant regions or lambda constant regions.

10. The antibody or antigen binding fragment of any one of claims 1-5, 9, wherein, The heavy chain constant region of the antibody or antigen-binding fragment has the amino acid sequence shown in SEQ ID NO:5, and / or the light chain constant region has the amino acid sequence shown in SEQ ID NO:

7.

11. The antibody or antigen binding fragment of any one of claims 6-9, wherein, The heavy chain constant region of the antibody or antigen-binding fragment has the amino acid sequence shown in SEQ ID NO:

10.

12. The antibody or antigen-binding fragment of claim 5 or 8, wherein, The at least 70% identity is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity; and / or the at most 15 mutations are at most 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 mutations; preferably, the mutations are selected from substitution, deletion, or insertion mutations; preferably, the mutations are reversion mutations or hotspot mutations; preferably, the substitutions are conserved amino acid substitutions.

13. The antibody or antigen binding fragment of any one of claims 1-12, wherein, The antibody or antigen-binding fragment is selected from monoclonal antibodies, polyclonal antibodies, natural antibodies, engineered antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, intact antibodies, fragments of intact antibodies, naked antibodies, conjugated antibodies, chimeric antibodies, humanized antibodies, fully human antibodies, Fab, Fab', Fab'-SH, F(ab)2, F(ab')2, Fd, Fv, scFv, diabody, or single-domain antibodies.

14. The antibody or antigen binding fragment of any one of claims 1-13, wherein, The LRRC15 is human LRRC15, monkey LRRC15 and / or mouse LRRC15.

15. The antibody or antigen binding fragment of any one of claims 1-14, wherein, The antibody or antigen-binding fragment further includes a conjugate; preferably, the conjugate is selected from therapeutic agents or tracers, preferably, the therapeutic agent is selected from radioisotopes, chemotherapeutic agents or immunomodulators, preferably, the tracer is selected from radiographic contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents and photosensitizers.

16. The antibody or antigen binding fragment of any one of claims 1-15, wherein, The KD value of the antibody or antigen-binding fragment binding to LRRC15 is less than 1E-08M, 1E-09M, 1E-10M, or 1E-11M.

17. A multispecific antigen binding molecule, characterized in that, The multispecific antigen-binding molecule comprises the antibody or antigen-binding fragment as described in any one of claims 1-16; and other antigen-binding molecules that bind to antigens other than LRRC15, or other antigen-binding molecules that bind to LRRC15 epitopes different from the aforementioned antibody or antigen-binding fragments; preferably, the other antigen-binding molecule is an antibody or antigen-binding fragment. Preferably, the other antigens are selected from the group consisting of: (1) tumor-specific antigens (TSA) or tumor-associated antigens (TAA); (2) immune checkpoints; and (3) targets that recruit and / or activate immune cells. Preferably, the multispecific antigen-binding molecule is bispecific, trispecific, or tetraspecific; Preferably, the multispecific antigen-binding molecule is bivalent, tetravalent, or hexavalent.

18. A chimeric antigen receptor (CAR), characterized in that, The chimeric antigen receptor includes at least an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain includes an antibody or antigen-binding fragment as described in any one of claims 1-16 or a multispecific antigen-binding molecule as described in claim 17.

19. An immune effector cell, wherein, The immune effector cells express the chimeric antigen receptor of claim 18 and / or contain nucleic acid molecules encoding the chimeric antigen receptor of claim 18; Preferably, the immune effector cells are selected from T cells, NK cells (natural killer cells), NKT cells (natural killer T cells), monocytes, macrophages, dendritic cells, or mast cells; more preferably, the T cells are selected from cytotoxic T cells, regulatory T cells, or helper T cells. Preferably, the immune effector cells are autologous immune effector cells or allogeneic immune effector cells.

20. An isolated nucleic acid molecule, comprising, The nucleic acid molecule encodes the antibody or antigen-binding fragment of any one of claims 1-16, the multispecific antigen-binding molecule of claim 17, or the chimeric antigen receptor of claim 18.

21. A vector, comprising: The carrier comprises the nucleic acid molecule of claim 20.

22. A cell, comprising: The cell comprises the nucleic acid molecule of claim 20 or the vector of claim 21.

23. A method of making the antibody or antigen binding fragment of any one of claims 1-16, or the multispecific antigen binding molecule of claim 17, comprising, The method includes: (1) culturing the cells of claim 22, and / or (2) isolating antibodies or antigen-binding fragments, or multispecific antigen-binding molecules expressed by the cells.

24. A method of making the immune effector cell of claim 19, comprising, The method includes introducing a nucleic acid molecule encoding the chimeric antigen receptor of claim 18 into the immune effector cells, and / or initiating the expression of the chimeric antigen receptor on the immune effector cells.

25. A pharmaceutical composition comprising, The pharmaceutical composition comprises an antibody or antigen-binding molecule according to any one of claims 1-16, or a multispecific antigen-binding molecule according to claim 17, or a chimeric antigen receptor according to claim 18, or an immune effector cell according to claim 19, or a nucleic acid molecule according to claim 20, or a carrier according to claim 21, or a cell according to claim 22, or a product prepared by the method according to any one of claims 23-24; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent, or adjuvant.

26. Use of the antibody or antigen-binding fragment according to any one of claims 1-16, the multispecific antigen-binding molecule according to claim 17, the chimeric antigen receptor according to claim 18, the immune effector cell according to claim 19, the nucleic acid molecule according to claim 20, the carrier according to claim 21, the cell according to claim 22, the pharmaceutical composition according to claim 25, or the product prepared by the method according to any one of claims 23-24, in the preparation of a medicament for treating tumors or cancer; preferably, the tumor is a tumor expressing LRRC15; more preferably, the tumor or cancer is selected from one or more of the following tumors or cancers: lung cancer, pancreatic cancer, liver cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, gastric cancer, esophageal cancer, nasopharyngeal carcinoma, kidney cancer, cervical cancer, prostate cancer, bladder cancer, uterine cancer, melanoma, head and neck cancer, bile duct cancer, thyroid cancer, ovarian cancer, glioblastoma, or sarcoma.

27. A method of treating a tumor or cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-26. The method includes administering an effective amount of a drug to a subject, the drug comprising an antibody or antigen-binding fragment according to any one of claims 1-16, a multispecific antigen-binding molecule according to claim 17, a chimeric antigen receptor according to claim 18, an immune effector cell according to claim 19, a nucleic acid molecule according to claim 20, a carrier according to claim 21, a cell according to claim 22, a pharmaceutical composition according to claim 25, or a product prepared by the method according to any one of claims 23-24. Preferably, the tumor is a tumor expressing LRRC15; more preferably, the tumor or cancer is selected from one or more of the following tumors or cancers: lung cancer, pancreatic cancer, liver cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, gastric cancer, esophageal cancer, nasopharyngeal carcinoma, kidney cancer, cervical cancer, prostate cancer, bladder cancer, uterine cancer, melanoma, head and neck cancer, bile duct cancer, thyroid cancer, ovarian cancer, glioblastoma, or sarcoma.

28. The antibody or antigen binding fragment of any one of claims 1-16, the multispecific antigen binding molecule of claim 17, the chimeric antigen receptor of claim 18, the immune effector cell of claim 19, the nucleic acid molecule of claim 20, the vector of claim 21, the cell of claim 22, the pharmaceutical composition of claim 25, or the product produced by the method of any one of claims 23-24, wherein, For the treatment of tumors or cancer, preferably, the tumor is a tumor expressing LRRC15; more preferably, the tumor or cancer is selected from one or more of the following tumors or cancers: lung cancer, pancreatic cancer, liver cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, gastric cancer, esophageal cancer, nasopharyngeal carcinoma, kidney cancer, cervical cancer, prostate cancer, bladder cancer, uterine cancer, melanoma, head and neck cancer, bile duct cancer, thyroid cancer, ovarian cancer, glioblastoma, or sarcoma.